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“For every complex problem 
there is a simple answer…but it’s 
wrong.” 
 
H.L Mencken 
 
“A book made of 
Steel...” 

  
ABSTRACT 
To combat lung cancer (LC) which is the number one cancer associated killer, a 
combination of surgery, chemotherapy, radiotherapy and targeted agents are currently 
used. The main subtype of LC, Non small cell lung cancer (NSCLC) unfortunately 
responds poorly to conventional radiotherapy (RT) for reasons yet only partly 
understood. Searching for the underlying mechanisms of RT-resistance has the 
potential to indentify signaling targets which can be used for radiosensitizing purposes. 
The overall aim of this thesis aims was to set up and use unsupervised global methods 
to gain novel insight of cellular signalling events responsible for the mechanisms 
controlling radioresistance in NSCLC cells and potentially find  radiosensitizing 
targets. In paper I we studied differences in NSCLC cellular response between 
irradiation of conventional low Linear Energy Transfer (LET) photons and high LET 
accelerated particles, which in the latter case induced an apoptotic response. A shotgun 
MS-based proteomics approach was used to analyze global protein expression after low 
and high LET ionizing radiation (IR). By applying the novel pathway search engine 
(PSE) on protein expression data, a JNK-pathway was suggested as a key event in 
apoptotic response to high-LET IR in these cells. Both JNK as well as additional 
molecules of the JNK-pathway i.e. MKK4 and 14-3-3α, were proven to be regulated. 
This study demonstrates that, in contrast to low LET IR, high LET IR can trigger 
activation of the JNK pathway, which in turn is critical for induction of apoptosis in 
these cells. In paper II genomic profiling was used to identify putative low LET IR 
sensitizing targets used by the staurosporin analogue PKC 412 in RT sensitization of 
NSCLC cells. Out of a several altered genes, suppressed Ephrin B3 expression was 
selected and further studied. We found that siRNA-mediated silencing of Ephrin B3 
resulted in increased senescence, apoptosis and mitotic catastrophe and combination 
with IR also decreased IR-mediated G2-arrest. In paper III and IV a phosphoproteomic 
method consisting of strong cat ion exchange (SCX) and TiO2-based fractionation 
followed by nano-LC mass spectrometry analysis was set up and used to further study 
the role of Ephrin B3 (Paper III) and reveal  signaling events which may further 
explain how high LET IR can overcome low LET IR resistance (Paper IV).  In paper 
III, this method in combination to network analysis found and verified  that silencing 
of Ephrin B3 in NSCLC cells results in loss of a specific phosphorylation on Ser 897 
on the erythropoietin-producing hepatocellular receptortyrosine kinase class A2 
(EphA2), a Eph kinase member shown to be upregulated in NSCLC patient tumor 
material. Moreover, inhibition of Ephrin B3 expression blocked phosphorylation on Ser 
129 of Akt1, a kinase previously implicated in regulation of Ser 897 on EphA2. Our 
data also support a process in which a Heat shock protein 90 isoform (HSP90AA1) acts 
as a protector of EphA2, thereby saving it from degradation. In paper IV the 
phosphoproteomic profiling of low and high LET irradiated U-1810 cells and 
subsequent pathway analysis suggested that in addition to JNK, down regulation of 
Akt-mediated survival signaling as well as impaired t-RNA synthesis and eIF-mediated 
protein translation may contribute to high LET IR induced apoptosis. Hopefully, when 
further validated these findings may have the potential of becoming clinically useful for 
RT sensitizing strategies of NSCLC.  
  
LIST OF PUBLICATIONS 
 
 
I. Stahl S, Fung E, Adams C, Lengqvist J, Mork B, Stenerlow B, Lewensohn R, 
Lehtio J,  Zubarev RA, Viktorsson K. Proteomics and pathway analysis 
identifies JNK signaling as critical for high linear energy transfer radiation-
induced apoptosis in non-small lung cancer cells. Mol Cell Proteomics 2009; 
8(5): 1117-29. 
 
 
II. Stahl S, Kaminiskyy V, Vaculova A, Efazat G, Rodriguez-Nieto S, Moshfegh 
A, Lewensohn R, Viktorsson K, Zhivotovsky B. Global gene analysis reveals 
Ephrin B3 as a potential radiosensitizing target in non-small cell lung 
carcinoma cells. Manuscript 
 
 
III. Stahl S, Mm Branca R, Efazat G, Ruzzene M, Zhivotovsky B, Lewensohn 
R.Viktorsson K, Lehtio J. Phosphoproteomic profiling of NSCLC cells reveals 
that ephrin B3 regulates pro-survival signaling through Akt1-mediated 
phosphorylation of the EphA2receptor. J Proteome Res 2011 Mar 17 
 
 
IV. Stahl S, Mm Branca R, Efazat G, Stenerlöw B, Lewensohn R, Lehtio J 
Viktorsson K. Phosphoproteomic profiling to explore differences in cellular 
response between high and low LET irradiated Non small cell lung cancer cells. 
Manuscript 
 
 
  
CONTENTS 
Abstract ........................................................................................................................... i 
List of publications ........................................................................................................ ii 
List of abbreviations .................................................................................................... iii 
 
1 INTRODUCTION ................................................................................................. 1 
1.1 WHAT IS CANCER AND WHY DOES IT KILL US? ............................. 1 
1.2 LUNG CANCER ........................................................................................... 2 
1.2.1 Lung cancer therapy today ............................................................... 3 
1.2.2 Radiotherapy ..................................................................................... 3 
1.2.3 Radioresistance in lung cancer - the molecular persceptive ......... 10 
1.2.4 Targeted therapy in lung ancer ....................................................... 11 
        1.3 THE IMPORTANCE OF PROTEIN PHOSPHORYLATIONS .............. 15 
1.3.1 Protein phosphorylations and cancer ............................................. 16 
1.4 GLOBAL METHODS TO STUDY CELL SIGNALING – THE 
OMICS ERA ......................................................................................................... 17 
1.4.1 Genomics ......................................................................................... 18 
1.4.2 Proteomics ....................................................................................... 19 
1.4.3 Phospshoproteomics ....................................................................... 20 
2 THE PRESENT STUDY ..................................................................................... 24 
2.1 AIMS ............................................................................................................ 24 
2.2 MATERIAL AND METHODS .................................................................. 25 
2.2.1 U-1810 cells as a model system to study radioresistance 
mechanisms in NSCLC  ................................................................... 25 
2.2.2 Low – and high LET irradiation ..................................................... 25 
2.2.3 RNA interference ............................................................................. 25 
2.2.4 Assays of cell fate ............................................................................ 26 
2.2.5 Gene array ....................................................................................... 26 
2.2.6 Enrichment of phosphorylated peptides using SCX-
fractionation and TiO2-magnitic beads ......................................... 27 
2.2.7 LTQ-FT mass spectrometry ............................................................ 27 
2.2.8 LTQ – Orbitrap Velos mass spectrometry ...................................... 28 
2.2.9 Data handling and validation ......................................................... 28 
        2.3 RESULTS .................................................................................................... 29 
2.3.1 Paper I ............................................................................................. 29 
2.3.2 Paper II ............................................................................................ 29 
2.3.3 Paper III........................................................................................... 30 
2.3.4 Paper IV ........................................................................................... 31 
        2.4 GENERAL DISCUSSION ......................................................................... 33 
2.4.1 Methodological and technical perspectives ................................... 33 
2.4.2 Biological perspectives ................................................................... 38 
        2.5 GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES ............ 43 
2.5.1 Future perspectives ......................................................................... 44 
3 ACKNOWLEDGEMENTS ............................................................................... 47 
4 REFERENCES .................................................................................................... 49 
 
 
  
LIST OF ABBREVIATIONS 
 
LC Lung cancer 
NSCLC Non small cell lung cancer 
RT Radiotherapy 
LET Linear Energy Transfer 
 PSA Pathway search engine 
IR Ionizing radiation 
SCX Strong cat ion exchange 
EphA2 Erythropoietin-producing hepatocellular receptortyrosine kinase 
class A2 
SCLC Small cell lung carcinoma 
SBRT Stereotactic body radiotherapy 
LD Limited disease 
ED Extensive disease 
SSB Single strand break 
DSB Double strand break 
HR Homologous recombination 
NHEJ Non-homologous end joining 
EGFR Epidermal growth factor receptor 
IGF-1R Insulin growth factor 1 receptor 
TKIs Thyrosin kinase inhibitors 
PTM Post translational modification 
P-ser Phosphorylated serine 
MS Mass spectrometry 
2D- gel 
electrophoresis 
Two-dimensional gel electrophoresis 
SELDI Surface enhanced lased desorption ionization 
MALDI Matrix associated laser desorption ionization 
pI Isoelectric point 
IMAC Immobilized metal affinity chromatography 
TFA Triflouracetic acid 
ACN Acetonitrile 
nanoLC-ESI  
DHB 
Nano-liquidchromatography-electrospray ionization 
2.5-dihydroxybenzoic acid 
CFSE Carboxyfluorescein succinimidyl ester 
LTQ Linear ion trap 
FT Fourier transform 
CID Collision induced dissociation 
HCD Higher energy collision dissociation 
ECD Electron transfer dissociation 
IPA Ingenuity pathway analysis 
 
   1 
1 INTRODUCTION 
  
 
1.1 WHAT IS CANCER AND WHY DOES IT KILL US? 
Cancer is the name for a group of diseases in which the cells become abnormal and 
divide without control. Cancer cells may invade nearby tissues and they may also 
spread through the bloodstream and lymphatic system to other parts of the body. 
Eventually when the tumor is growing and/or further spread it becomes malignant and 
lethally affects the invaded organs.  It can physically exercise significant press on vital 
organs and/or will use all energy and resources available which in the end is lethal to 
the body. One of the main problem when trying to stop cancer is that the tumor origin 
from ourselves and when trying to effectively kill and eradicate all cancer cells we are 
also killing our normal cells. It has emerged in the past years that tumors are more than 
just highly proliferating cancer cells. Instead, they are complex tissues composed of 
multiple distinct cell types that participate in heterotypic interactions with one 
another. In the tumor micro-environment -  there are also recruited normal cells, 
which form the tumor-associated stroma, as they are believed to be active participants 
in tumor genesis rather than passive bystanders (1). The reason why normal cells are 
transformed into cancer cells is due to genomic instability and somatic mutations also 
known as oncogenic dependency of the cancer cells. However, the events occurring 
during the transformation process is complex to overlook and grasp. Yet they 
comprises eight biological capabilities; sustaining proliferative signaling, evading 
growth suppressors, activating invasion and metastasis, enabling replicative 
immortality, inducing angiogenesis, resisting cell death, deregulating cellular energetics 
and avoiding immune destruction.  These capabilities constitute an organizing principle 
with the aim to provide a logical framework for understanding the remarkable diversity 
of neoplastic cells, namely the hallmarks of cancer (1). The transformation process and 
how it is regulated by, as well as how it is regulating the hallmarks depends in turn on 
the communication within and between cancer cells. Hence, to improve cancer therapy, 
it is crucial to understand the cancer and how it communicates – for that we need to 
understand the “language of cancer”. Thus, revealing cellular signaling events in the 
context of cancer is of outmost importance. Hopefully, this thesis can contribute a piece 
of the enormous puzzle that needs to be finished. 
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1.2 LUNG CANCER 
Although lung cancer is not the most common tumor form, it is the major cause of 
cancer-related death in men and women and is annually responsible for 1.3 million 
deaths worldwide (2-3). The possibility for a patient diagnosed with lung cancer to 
survive more than five years is only 15% and at the late stage lung cancer only 5% (4). 
The most common cause of lung cancer is long-term exposure to tobacco smoke (figure 
1) However, still as many as 15% of lung cancer cases occurs in nonsmokers and  is 
then often attributed to a combination of genetic factors, radon gas, asbestos, and air 
pollution including secondhand smoke (5).The most common symptoms are shortness 
of breath, coughing and weight loss. The vast majority of primary lung cancers are 
carcinomas of the lung, derived from epithelial cells, where the main types are small 
cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). This 
distinction is important, because the treatment varies; NSCLC constitutes 80 % of lung 
cancer cases and is more often diagnosed earlier and can sometimes be treated with 
surgery but otherwise often responses poorly to conventional radiotherapy and 
chemotherapy (4), while SCLC initially responds better to chemotherapy and radiation 
but resistant clones unavoidably start to grow again and the disease becomes rapidly 
aggressive.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1: Cancer of the lung from a heavy smoker (picture: from public domain 
Wikimedia commons). 
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1.2.1 Lung cancer therapy today 
Treatment of lung cancer depends on the clinical stage at diagnosis. For NSCLC the 
first hand choice is radical surgical resection of the primary tumor for both stage I and 
II, this is obtained by the removal of the lung lobe or sometimes the entire lung(6) 
(figure 1). In non-operable cases Stereotatctic body radiothearapy (SBRT) is given with 
curative intent in stage I (7) and chemotherapy in stage II. In stage III chemotherapy 
and radiotherapy is given (8-9) whereas palliative chemotherapy or biological agents 
are used in stage IV. SCLC is only classified as limited disease (LD) or extensive 
disease (ED), in case of LD a combination of chemotherapy and radiotherapy is used 
(10) while only palliative chemotherapy is given in ED (11). 
 
 
1.2.2 Radiotherapy 
Radiotherapy (RT) or ionizing radiation (IR) used for therapeutic purposes mainly 
consists of X or γ-rays in which the radiation is delivered by photons and which is 
termed low Linear Energy Transfer (LET) which indicate that it induces few 
ionizations per the unit of length it traverse (given as keV/µm) (12-13). Photons deposit 
their energy in the matter they traverse e.g. in cellular membranes, cellular cytosol or 
the DNA. The release of energy results in fast moving electrons which subsequently 
causes ionizations or breakage of chemical bonds (12). Another type of radiation 
quality which in some cases are used for tumor therapeutic purposes is high LET 
accelerated particles such as charged particles of boron, carbon or neon ions which 
have an energy content of above 100 keV/µm as compared to low LET IR which don’t 
exceed 1 keV/µm. 
 
The critical cellular target of IR is the DNA as it contains the genetical material and if 
DNA is damaged by IR in an unrepairable way genetic information may be lost 
resulting in either mutation or cell death. Both low and high LET IR may cause 
different types of DNA damages including DNA single and DNA double strand breaks 
(DNA SSBs and DNA DSBs respectively), DNA base damages, sugar damages as well 
as DNA-DNA cross links and DNA-protein cross links. For 1 Gy of low LET IR, it is 
estimated that it causes 1000 base damages, 1000 DNA SSBs and about 40 DNA DSB 
per nucleus it traverse (12). Yet the induced DNA DSBs are the most detrimental as 
they if not repaired properly will result in loss of genetic information. Indeed results 
have demonstrated that a direct correlation exists between the number of DNA DSB 
formed and loss of clonogenic survival in irradiated cells (14-15). 
As indicated by low LET nomenclature γ-rays photons induces few direct ionizations 
which are randomly distributed within the DNA (16) (Fig.2). Instead most of the low 
LET IR- induced DNA DSBs is a result of hydroxyl radicals formed when fast 
moving electrons ionizes water (16) (Fig.2).  
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Figure 2: Ionization of low and high LET IR. Low LET photons mainly exert DNA 
DSB formation by indirect effects in which ionization of water produces hydroxyl 
radicals which subsequently cause DNA DSBs. In contrast high LET accelerated 
particles cause’s dense ionizations along the tracks causing complex DNA DSBs to be 
formed. For details see text. 
 
 
As solid tumors can outgrow their blood supply, causing a low-oxygen state known 
as hypoxia, a state which accordingly impairs the effect of low LET IR this may 
cause tumor cells to be as as much as 2 to 3 times more resistant to low LET IR-
induced DNA DSBs than those in a normal oxygen environment (17). In contrast to 
low LET, high LET charged particles such as nitrogen, boron, carbon or neon ions 
(high LET IR) act mostly via direct energy transfer into the DNA causing a higher 
number of ionizations for a given dose, hence a higher amount of DNA DSBs and 
also DNA DSBs with greater complexity (18-19) (Fig.2). Moreover, as high LET IR 
can induce DNA DSB directly, it is likely less influenced by oxygen status of the 
tumour.  
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Molecular signaling circuits induced by IR 
 DNA DSBs are the most critical type of DNA damage as it if left unrepaired may 
cause mutations or cell death. Hence, cells are equipped with “emergency systems” in 
the form of cellular signaling to handle the detection and repair of these DNA DBSs. 
Although both high and low LET induced DNA DSBs activate these signaling cascades 
some of the molecular components demonstrated to have a critical role in response to 
low LET IR are reported to be dispensable for efficiency of high LET IR. One  example 
of such a component is the tumor suppressor p53 (20-22) and onother is the DNA-
repair protein DNA-PK (23).  
 
The simplified view is that IR-induced DNA damages trigger cell cycle arrest allowing 
DNA repair to take place and if the DNA damage is too severe, cell death is induced. 
Yet the molecules which are responsible for directing the cell towards repair of the 
DNA damage, towards survival or towards cell death i.e. the so called decision makers 
are not completely elucidated. Nevertheless, four principal signaling cascades can be 
seen activated in response to IR (Fig.3): (I) DNA DSB detectors, (II) cell cycle 
checkpoints regulators which halt the cell cycle, (III) DNA DSB repair pathways and 
(IV) cell death regulating proteins.  
 
A number of different proteins are involved in recognition including BRCA1/2, the 
Mre11/Rad50/Nbs1 (MRN) complex and the Ataxia telangiectasia mutated (ATM) 
kinase (Fig.3). ATM is a member of the phosphatidylinositol-3-kinase (PI3K) family 
(24) and was cloned from patients with the autosomal recessive disorder ataxia 
telangiectasia (AT) whose cells were found to display genetic instability and 
increased radiosensitivity (25). ATM has been shown to reside in undamaged cells in 
an inactive dimer and in response to DNA DSBs, most likely as a consequence of 
chromatin structure changes, these dimers phosohorylate each other with the net 
outcome of active ATM monomers (26). The active monomers of ATM are then 
interacting with the Mre11/Rad50/Nbs1 (MRN) complex at the site of the DNA DSB 
allowing its full activation and capacity to phosphorylate different downstream 
substrates (27). Among the different substrates are the DNA DSB marker H2AX 
resulting in H2AX (28) and the Chk2, an important IR-activated G2 cell cycle 
checkpoint protein (29) (Fig.3).   
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Figure 3: Molecular signaling circuits activated in response to radiation. For 
details see text.  
 
 
With respect to IR-induced cell cycle regulation two principal responses may occur, i.e. 
activation of a G1 arrest or activation of the G2 checkpoint. The tumor suppressor 
protein p53 is an important regulator of both cell cycle responses after IR and is also 
instrumental for induction of senescence and apoptotic cell death (see below). In order 
to exert these tasks, p53 expression needs to be elevated as low levels are found in non 
stressed cells. In response to IR-induced DNA DSBs this achieved by phosphorylation 
of p53 on different residues by ATM (30) DNA-PK(31) and Chk2 (32) thereby 
alleviating the association with the negative regulator Mdm-2 and resulting in increased 
p53 levels (reviewed in (33)).  
 
p53 is instrumental in IR-mediated cell cycle control as it causes transcriptional 
activation of p21WAF1/Cip1, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6) 
(34) and as a net result the phosphorylation of retinoblastoma protein (Rb) is blocked 
and hence the release of E2F transcription factor driving S phase entry is inhibited. 
Importantly, in many tumors this IR-induced G1 arrest is lost as they display mutations 
in p53 which impairs its capacity to induce p21WAF1/Cip1 transcription. This is also true 
for LC in which p53 mutation is one of the most frequently found genetic alteration 
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identified in about 70% of all SCLC and in 50% of NSCLC cases respectively (35). 
Whereas the IR-induced G1-arrest mainly is controlled by p53 and hence frequently is 
lost in tumors, IR-induced G2/M cell cycle control is executed by p53-dependent and 
independent pathways in which the cyclin dependent kinase Cdc2, an essential kinase 
for mitotic entry, is the primarily regulated component but where is binding partner 
cyclin B is also interfered with (reviewed in (36)).  
 
 Apart from DNA DSB recognition and cell cycle arrest, the activation of the two 
complementary DNA DSB repair pathways homologous recombination (HR) and non-
homologous end joining (NHEJ) (37) are of importance for the cellular response to IR. 
Whereas HR, which make use of the sister chromatid in repair of the DSB can act only 
in late S and G2 phase when such a template is available NHEJ may work also on DNA 
DSBs formed in different cell cycle phases (38). In short, the HR starts by recruitment 
of ATM and BRCA1/2 to the site of the DNA DSB forming the BASC complex 
which subsequently recruits Nbs1, Rad 50 and MRE11into the MRN complex (39) 
(Fig.3). Thereafter RPA is binding to this complex and homology search between the 
sister chromatides occurs followed by strand inversion, DNA synthesis, and 
relegation of the DNA strand (39).  
 
By activating and utilizing NHEJ, cells may efficiently repair IR-induced DNA DSBs 
in different cell cycle phases primarily in G0/G1 but in an error prone way as no error 
free DNA copy is used as template (40). The principal steps in NHEJ is the binding of 
the free DNA ends within the DNA DSBs by the ku heterodimers KU80/KU70 which 
results in the recruitment of the phosphatidylinositol-3-kinase (PI3K) family kinase 
DNA-PKcs (41-43). The critical role of NHEJ in determining cellular IR sensitivity is 
illustrated by rodent and human cells lacking either DNA-PKcs or KU-proteins all 
which display a degree of IR sensitivity relative to their parental cell lines (44-46, 47 ).  
 
The fourth principal signaling cascades activated in response to IR is the triggering of 
different cell death processes within tumor cells which roughly can be divided into cell 
cycle independent and mitotic cell death which is induced in response to residual DNA 
DSBs and/or other DNA damages. The mode of cell death can in either case be 
apoptosis, autophagy, mitotic catastrophy followed by apoptosis, necrosis or 
senescence and which path the tumor cells choose is not entirely clear but may depend 
on tissue of origin, amount of and how severe the DNA damage is as well as of the 
signaling circuits functionally operating within irradiated cells (reviewed in (48)). Thus 
it is shown that thymocytes and cells of hematopoetic origin respond to IR with a rapid 
induction of apoptosis (49). In contrast, IR may in solid tumor cells primarily causes 
growth arrest (either in G1 or G2 dependent on p53 status) followed by at least in some 
cases mitotic catastrophe in which cells with unresolved DNA DSBs cannot divide 
resulting in giant cells which later either die by apoptosis or by necrosis.  
 
The morphological hallmarks of apoptosis was described by Kerr, Wyllie and Currie  in 
1972 as plasma membrane blobbing, cell shrinkage, condensation/fragmentation of the 
chromatin, and disintegration of the cell into apoptotic bodies (50).  It has through 
 8 
extensive analysis become evident that all these characteristics are result of selective 
proteolysis of cell signaling, DNA-repair as well as structural proteins executed by a 
group of cystein-aspartate enzymes named caspases (51). Thus both the DNA DSB 
repair protein DNA-PK and the DNA SSB repair protein Poly (ADP-ribose) 
polymerase (PARP) are subjected to caspase-mediated cleavage, as is the caspase 
activated DNAase (CAD) which results in the characteristic DNA fragmentation of 
apoptosis (51-52).  
 
The caspases are divided into initiator caspases i.e. caspase-2, -8, -9, and -10 and 
effector caspases i.e. caspase-3, -6, and -7 the former being activator of the later which 
subsequently carries out the selective substrate proteolysis. Two principal pathways 
may causes caspase activation either the extrinsic pathway in which death ligand 
binding to the a death receptor e.g. Fas ligand to the Fas receptor causes receptor 
oligomerization, adaptor protein recruitment and formation of a complex with pro-
caspase-8 which then undergoes autoproteolytical cleavage into active caspase-8 which 
directly or indirectly can cause caspase-3 activation (53) (Fig.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
       Figure 4: Apoptotic signaling events in response to IR. For details see text.  
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However, for IR-induced apoptosis multiple evidence points towards a critical role for 
the intrinsic activation of caspases i.e. via mitochondrial release of apoptogenic proteins 
e.g. cytochrome c and Smac/DIABLO from the inter membrane to the cytosol (54) 
(Fig.4).  Within the cytosol the released cytochrome c forms a complex together with 
apoptosis protease-activating factor 1 (Apaf-1) and dATP, the apoptosome in which 
several procaspase-9 are brought in close proximity allowing their activation into 
caspase-9 (55-56). Subsequently caspase-9 triggers caspase-3 activation and the 
apoptotic hallmarks can be observed.  
 
The release of cytochrome c from mitochondria which is critical for activation of the 
intrinsic pathway of apotosis is highly controlled by among other the Bcl-2 family 
proteins. (Fig.4). The Bcl-2 family proteins comes in two principal flavors,  an anti-
apoptotic group exemplified by  Bcl-xL and Bcl-2 and a proapoptotic group which 
consists of the multidomain proteins Bak and Bax and the BH3-only proteins 
exemplified by Bid, Bim, Bad, PUMA, and NOXA (57). The critical role for Bak and 
Bax but also their redundant function in DNA-damage induced apoptosis is illustrated 
by the impaired apoptotic response of mouse embryo fibroblasts (MEFS) with targeted 
deletion of Bak and Bax to the DNA DSB-inducing agent etoposide (58). Moreover, it 
has been demonstrated that in response to DNA damage, Bax undergo N-terminal 
conformation changes allowing its integration into the outer mitochondrial membrane 
(Fig.4) (59-60) and enabling it to form a multimeric homo- or heterocomplex with Bak 
allowing release of cytochrome c (61-62). Similarly, Bak, which already reside in the 
mitochondria, undergoes several N-terminal conformational changes allowing its 
multimerization and interaction with Bax (60, 62-65). The current view is that the  
antiapoptotic proteins Bcl-2 and Bcl-XL inhibits the multimerization of Bak and Bax 
and that the BH3-only proteins act by antagonizing this effect (57) (Fig.4). Moreover, 
the BH3-only proteins play a critical role as they function to integrate signals from both 
DNA-damage as well as from growth factor receptors onto Bak and Bax (57). Thus the 
tumor suppressor p53 which is activated by DNA DSB as described above, may not 
only induce transcriptional activation of  Bax and repression of Bcl-2 but also induces 
transcription of the BH3 proteins NOXA (66) and PUMA (67-68) and thereby tilt the 
balance towards a pro-apoptotic response. Tumor cells which normally are 
characterized by high growth factor receptor signaling e.g. Epidermal growth factor 
receptor (EGFR) or Insulin growth factor 1 receptor (IGF-1R) may also have impaired 
apoptotic circuits as the BH3-only protein Bad when phosphorylated by the survival 
kinases Akt and MAPK ERK is blocked in its proapoptotic function by binding to 14-
3-3 (69-70). 
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1.2.3 Radioresistance in lung cancer - the molecular perspective  
 
Inherent resistance to chemo-and radiotherapy (CT/RT) is frequently observed among 
NSCLC patients and complete response to therapy is unusual. The underlying 
mechanism on the molecular level is likely a combination of several factors such as 
for example (I) deregulated growth factor signaling which may impede apoptotic 
response e.g. EGFR-mediated activation of Akt resulting in Bad inactivation, (II) 
increased DNA-repair capacity enabling cells to circumvent CT-or RT-induced DNA 
damages as well as (III) impaired function of cell death signaling pathways. 
 
With respect to increased growth factor signaling and RT resistance of NSCLC, 
deregulation of EGFR signaling is of course of importance and EGFR signaling will 
be further discussed below in section 1.2.4.  Yet another growth factor receptor which 
may be instrumental for RT resistance of NSCLC is Insulin growth factor 1 receptor 
(IGF-1R) as demonstrated by earlier findings from our group (71-73). Thus it was 
shown that in NSCLC U-1810 cells a combination of IGF-1R inhibition and RT 
caused synergy with respect to cell death and resulted in an increased G2 cell cycle 
accumulation (73). In yet other NSCLC cell lines IGF-1R inhibition and RT were 
reported to be additive with respect to cell death. Interestingly, it was also 
demonstrated that RT actually activated IGF-1R as early as 10 minutes after IR with a 
maximal activation effect 2 h post-irradiation and that IGF-1R in its active form bind 
and activate p38MAPK thus suggesting that growth factor receptor signaling may 
indeed most likely directly be activated by IR (71) which recently also was reported 
for EGFR (74). Importantly, blocking IGF-1R with small molecule kinase inhibitor 
was found to disrupt IGF1-R/p38MAPK complex, block MAPKp38 activity and to 
sensitize for RT-induced cell death illustrating that targeting growth factor receptors 
may overcome NSCLC RT resistance (71).   
 
Moreover, the downstream targets of growth factors such as PI3K/Akt signaling has 
also been demonstrated to confer RT resistance  as reviewed in (75) and shown in 
(76-77). Thus Brognard et al., showed that NSCLC often have constitutively 
activation of Akt with phosphorylation of S473 as a result of increased PI3K activity. 
Importantly by inhibiting PI3K using LY294002 an additive effect on IR-induced 
cytotoxicity as well as on IR-induced apoptosis was observed (76). Similarly our 
collaborators in the Zhivotovsky group demonstrated that targeting Akt1 as well as 
MAPK ERK-1 indeed sensitized for DNA DSB inducing treatments in some but not 
all NSCLC cell lines tested (77) thus further suggesting a role for Akt1 and at least in 
some cases, MAPK ERK in RT resistance of NSCLC.  
 
In addition, our group previously showed that expression and activity of the DNA-
repair enzyme DNA-PKcs as well as rejoining of IR-induced DNA DSBs may be 
correlated to intrinsic RT resistance of a panel of SCLC cell lines (78). Moreover, it 
has been demonstrated that inhibiting DNA repair capacity of NSCLC can sensitize 
for treatments inducing DNA DSB (79).  
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Last but not least, RT resistance mechanisms of LC may of course be a result of 
deregulated cell death pathway signaling including apoptotic signaling as 
demonstrated by our group and others previously (65, 77, 80-87) and further 
emphasized in this thesis (Paper I, II and IV) using a signalomics approach. 
Nevertheless, in part this deregulation may be a result of increased growth factor 
signaling as Raf, Akt as well as MAPK ERKs are known to regulate the BH3 only 
protein Bad and impeding its proapoptotic function (69-70). Yet results also suggest 
that failure of IR-induced apoptosis in LC may indeed by a result of Bak and Bax 
activation directly as well as of lack of SAPK JNK activation (65).  
 
 
1.2.4 Targeted therapy in Lung Cancer 
To circumvent resistance and improve survival rate in current clinical practice, there is 
an urgent need for more targeted and individualized therapies that impact the tumor-
driving cellular pathways from multiple angles. The Epidermal growth factor receptor 
(EGFR) is overexpressed in NSCLC and has been extensively studied (88) . Inhibitors 
of this receptor have recently reached the clinic but are only beneficial in a limited 
group of patients. Yet other signaling aberrations in NSCLC which have been explored 
for targeted therapy approaches include Insulin-like growth factor 1 receptor (IGF-1R), 
the mTOR pathway and the fusion protein EML4-ALK (89). The erythropoietin-
producing hepatocellular (Eph) receptors and their corresponding ligands, ephrins 
have recently been acknowledged as a potential signaling network of importance in 
tumors in general and in NSCLC in particular. EphA2 is an upcoming candidate which 
together with the ligand ephrin A1 shows promising preclinical results as potential 
targets in NSCLC therapy.  
 
Targeting EGFR 
NSCLC is frequently associated with EGFR overexpression, which occurs in 40–80% 
of the patients (90-94) and a high EGFR copy number is found in 30–60 % of cases 
(95-96). EGFR has a role in activating two major pathways in solid tumors, the 
PI3K/Akt/mTOR pathway, and the RAS/RAF/MEK/MAPK pathway (Fig 5) (97). 
These signaling pathways are important in tumor cell growth, local invasion, 
angiogenesis, protein translation, and cell metabolism (98). Consequently, EGFR-
blocking strategies have been enthusiastically investigated during the past decade. 
 
While the development of first-generation EGFR thyrosin kinase inhibitors (TKIs) has 
been a major accomplishment in targeted NSCLC therapy, only a fraction of  patients 
respond to Erlotinib or Gefitinib. Primary resistance is problematic, but acquired 
resistance, which occurs after an initial response, is also common, and may result from 
redundant or overlapping signaling pathways. In addition, none of the four large Phase  
III trials i.e. Iressa NSCLC Trail Assessing Combination Treatment [INTACT] 1, 
[INTACT] 2, Tarceva Lung Cancer Investigation [TALENT] and Tarceva Response in 
Conjugation with Paclitaxel and Carboplatin [TRIBUTE], which evaluated the addition 
of erlotinib or gefitinib to chemotherapy as first-line therapy in patients with NSCLC  
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reported a survival benefit with the EGFR TKI (99-102). (99-102). Recent molecular 
and clinical studies have revealed that EGFR-TKIs are mainly effective in tumors 
bearing specific EGFR mutations in the gene region coding for the ATP-binding 
domain, which corresponds also to the binding site of the TKIs. In addition, tumors 
treated with gefitinib or erlotinib usually develop an additional “resistance” gene 
mutation which makes EGFR insensitive to inhibition by these drugs. Next generation 
inhibitors of EGFR have been developed using novel strategies that may improve 
efficacy; these include irreversible inhibition, targeting more than one EGFR family 
member, and simultaneous targeting of EGFR and other tumorigenic pathways (88). 
However, it is obvious that more candidates for targeted therapies in NSCLC are highly 
warranted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Figure 5: EGFR-signaling is targeted by inhibition in NSCLC-therapy. 
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The emerging role of EphA2 as a target for NSCLC therapy 
Receptor tyrosine kinases functioning as proto-oncogenes often display increased 
activity and play an essential role in the cell signaling pathways in carcinogenesis 
(103-105). While several tyrosine kinase receptors like EGFR have been documented 
and targeted for their critical role/s in tumorigenesis (106), the cell-membrane-bound 
EphA2 receptor, a member of the erythropoietin-producing hepatocellular (Eph) 
tyrosine kinases receptor family, has generated great interest only in the last few 
years. The Eph family is the largest group among the tyrosine kinase receptor families 
and is comprised of the EphA (EphA1-10) or EphB (EphB1-6) subclasses of 
receptors classified with regard to their sequence homologies and their binding 
affinity for their ligands - the ephrins (107-109). The first member of Eph family was 
cloned from an erythropoietin-producing hepatocellular cancer cell line in 1987 and 
was named as EphA1 (110). A few years later, in 1990 EphA2 was identified by the 
screening of a human epithelial cDNA library (111) and it was established that the 
human EphA2 gene encodes a receptor tyrosine kinase of 976 amino acids with an 
apparent molecular weight of 130 kDa (112). The Eph family contains an 
extracellular conserved N-terminal ligand-binding domain followed by a cysteine rich 
domain with an EGF-like motif and two fibronectin type-III repeats. The extracellular 
motif is followed by a membrane-spanning region and a cytoplasmic region that 
encompasses a juxtamembrane region with a tyrosine kinase domain (113-116). 
EphA2 shows 25 - 35% sequence homologies with other Eph receptors, and the 
tyrosine residues are conserved within the juxtamembrane and kinase domain (113, 
117).  
 
The ligands for Eph receptors, the ephrins, are divided into two subclasses ephrinA 
(ephrinA1 - 6) and ephrinB (ephrinB1 - 3) (114-115). EphrinA members are anchored 
to the plasma membrane by a glycosylphosphatidylinositol (GPI) linkage while 
ephrinB members have a transmembrane and a cytoplasmic domain.  Ephrin A1 is the 
most storied ligand of EphA2 and was found to be a ligand for the receptor based on 
its ability to bind the extracellular domain of the EphA2 receptor when tagged to an 
affinity column (118). EphrinA1 is a GPI-anchored protein with an apparent 
molecular weight of 28 kDa and shows 30 - 40% amino acid similarities with other 
ephrins (119-120). Eph-ephrin signaling functions like the classical tyrosine kinase 
receptor-mediated cell signaling where a cell bearing an Eph receptor upon binding to 
ephrin ligand transmits signals downstream known as forward signaling. In addition, 
intracellular signals in backward direction are also generated in ephrin-bearing cells 
known as reverse signaling. Accordingly, a contact between two communicating cells 
and a clustering of membrane-bound ephrin ligands is required for the Eph--ephrin 
bidirectional signaling (121-122). EphrinA1 organizes into micro-clusters upon 
association of an EphA2 receptor and actin cytoskeleton on the adjacent cell (123-
124). The crystal structures of EphA2 extracellular domain also suggest that EphA2 
localization at the cell-cell contacts depends on the clustering of EphA2, and a high 
concentration of EphA2 clustering independent of the ephrin ligand could impart a 
phenotype typical of a cancerous cell (125). The role of Eph-ephrin signaling has  
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been studied in great detail in the development of the nervous system and spans a 
wide range of functions such as the development of neuronal networks, axon 
guidance, formation and remodeling of synaptic connections, and nervous system 
repair (121). Properties harbored by developmental proteins are by their nature likely 
to be of importance also for cancer cells. Hence, understanding of EphA2 and how it 
is regulated especially in the context of its interplay with EGFR is most likely to be 
important when developing new strategies for NSCLC cancer therapeutics. 
 
EphA2 have recently been found overexpressed in several cancer forms including lung. 
Hence, during the past two years, this receptor has gained lots of attention as an 
impending target for cancer therapy. In a retrospective NSCLC cohort, moderate to 
high immunostaining of EphA2 has been observed in the membrane and cytoplasm in 
more than 70% of the carcinomas(126). This increase is similar in adenocarcinoma, 
squamous cell carcinoma and large cell carcinomas. The highest level of EphA2 is 
observed in clinically advanced stages of disease, and the patients with increased 
EphA2 levels showed a poorer prognosis compared with patients with reduced 
EphA2 levels. Additionally, patients with brain metastasis of NSCLC displayed high 
levels of EphA2. EphA2 overexpression was also correlated with poor survival and a 
history of smoking (127).  
 
Effects of suppressing EphA2 in cancer 
To suppress EphA2 overexpression, sequence-specific silencing of EphA2 gene 
expression has been tested with many RNA interference (RNAi) approaches. In 
pancreatic adenocarcinoma-derived MIA PaCa2 cells, EphA2 expression was 
suppressed by RNAi, and it also inhibited tumor growth in a nude mice xenograft 
model (128). By weekly treatment with EphA2-specific siRNA, tumor growth was 
retarded by 70% in six weeks coincidently with an increase in caspase 3 activity and 
presence of apoptotic cells (128). In human glioma-derived U-251 cells, suppression 
of EphA2 by RNAi reduced cell proliferation and increased caspase 3 activity and 
apoptosis (129). EphA2 is also regulated by EGFR signaling in the EGFR 
overexpressing human head and neck carcinoma-derived cell line -  HN5. In line with 
this, in the human epidermoid-derived cell line, A-431, also EphA2 levels are 
increased when EGFR is activated by EGF. In HN5 cells, suppression of EphA2 
expression by RNAi significantly decreased EGF-induced migration in vitro wound 
healing assays. These results indicate that targeting EphA2 reduces EGFR-mediated 
cancer cell migration and strengths the theory of a cross-talk between EphA2 and 
EGFR signaling (130-131). Together, these studies demonstrate RNAi-mediated 
EphA2 suppression as a viable approach targeting EphA2 overexpressing cancers.  
 
The differential expression of EphA2 with substantially high levels in cancer cells 
compared with normal cells is documented in cell lines, and clinical specimens 
derived from cancer patients with several types of cancers indicate a generalized 
importance of EphA2 in carcinogenesis (132). The mechanisms by which EphA2 
overexpression occurs and then contributes towards cancer phenotype are not entirely  
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clear and depend on the genomic context and cell type-specific function in different 
cancers. Nonetheless, the studies discussed above point towards the role of oncogenic 
signaling transduction pathways coupled with the contributions of crosstalk with 
other receptor tyrosine kinases. Importantly, the tyrosine phosphorylation of EphA2 
resulting in its degradation and turnover has important functional consequences in 
tumor biology (132). EphA2 overexpression, functional alterations and gain of 
oncogenic function provide an opportunity to target EphA2 for therapeutic 
intervention. Thus, targeting EphA2 overexpression in preclinical studies of various 
cancer forms are  already showing promising results and have so far been done e.g. 
by EphA2 antibodies, RNAi, and small-molecule inhibitors (132).  
 
 
1.3 THE IMPORTANCE OF PROTEIN PHOSPHORYLATIONS 
Protein phosphorylation is one of the most widespread regulatory mechanisms in 
nature. It is a key regulator of intracellular biological processes and at present, it is the 
most studied and best understood post translational modification (PTM) (133-134). 
Protein phosphorylation regulates cellular signaling and communication and is known 
to be involved in controlling diverse processes including metabolism, transcriptional, 
and translational regulation, degradation of proteins, proliferation, differentiation, and 
cell survival (105, 135). Phosphorylation events frequently initiate and propagate signal 
transduction pathways. It is a transient, reversible PTM that typically leads to changes 
in the conformation, activity, and interactions of a protein within a very short 
timeframe. Since the modification is reversible, changes in protein activity can be 
tightly controlled in response to cellular or environmental stimuli. Phosphorylation 
often occurs at multiple residues within a protein and in most cases by different protein 
kinases. Multiple sites of phosphorylation allow a protein to adapt several different 
functions, depending on which phosphorylation site becomes occupied. For example, 
phosphorylation at one particular amino acid may lead to conformational changes that 
in turn allow for the phosphorylation of different amino acid residues within the same 
protein, or it can prevent the phosphorylation of nearby amino acids through sterical 
hindrance. Phosphorylation is regulated by a complex interplay between specific 
protein kinases and protein phosphatases, which keep a strict temporal and spatial 
control of the phosphorylation and dephosphorylation events at specific sites in target 
proteins. In eukaryotes, phosphorylation takes place at serine, threonine, or tyrosine 
residues and genomic sequencing has revealed that 2–3% of all eukaryotic genes are 
likely to code for protein kinases (136) and in addition, gene annotation have predicted 
more than 100 human protein phosphatases (137). At present, no studies have been able 
to elucidate how many proteins are in fact regulated by phosphorylation, but it has been 
estimated that more than 50 percent of all proteins are phosphorylated during their 
lifetime (134), and that more than 100 000 phosphorylation sites may exist in the 
human proteome. Despite its ubiquitous role, phosphoproteins are generally present at 
relatively low abundance within the cell and phosphorylated forms of individual 
proteins also tend to be present at much lower ratios than their non-phosphorylated 
counterparts. Due to the central regulatory role phosphorylation plays in maintaining  
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the dynamics of a living cell, it is crucial to develop analytical methods and strategies 
for the characterization of phosphorylated peptides. However, low relative abundance 
of many phosphoproteins, low phosphorylation stoichiometry and the dynamic 
regulation of phosphoproteins put high demands on the analytical methods required for 
the studies of phosphoproteins. Sensitive, comprehensive and highly specific analytical 
strategies are needed in order to characterize a meaningful number of modified 
proteins, including those present at very low abundance. 
 
1.3.1 Protein phosphorylations and cancer 
It is well known that dysregulation of kinase signaling pathways is commonly 
associated with various cancers (138). Aberrations in kinases have been reported in 
several cancers including gastrointestinal stromal tumors (139), lung cancer (140), 
haematologic malignancies (141), breast cancer (142), pancreatic cancer (143) and 
prostate cancer (144). This aberrant regulation may result from overexpression of 
kinases, mutations or defects in negative regulatory mechanisms, among others. 
Activated kinases can be specifically targeted using small molecule inhibitors. 
Examples of such targeted therapeutic approach employing small molecule kinase 
inhibitors have been previously reported in various cancers including chronic 
myelogenous leukemia (CML) (145-146), small cell lung cancer (147), breast cancer 
(148-149), non-small cell lung cancer (150) and melanomas (151). Personalized 
medicine in the context of cancer therapy is illustrated by the use of imatinib in CML 
and erlotinib in non-small cell lung cancer through blockade of Abl and EGFR, 
respectively. A number of proteomic approaches have been developed over the years to 
identify aberrantly activated kinases and their downstream substrates. Most often, but 
not always, phosphorylation is used as a surrogate for monitoring kinase activity in 
cells. Direct involvement of protein kinases in cancers came from the discovery of v-
SRC oncogene (152). The corresponding oncoprotein was later purified and found to be 
a protein kinase that undergoes phosphorylation (153-154). Subsequent biochemical 
studies revealed that Src was a tyrosine kinase (155-156). In fact, the transforming 
proteins of a number of avian and mammalian retroviruses were later found to possess 
tyrosine kinase activity (157-158). Tyrosine phosphorylation of host cellular proteins 
by viral kinases and their apparent involvement in cellular transformation was 
established using Rous sarcoma and Abelson murine leukemia viruses (159-161). To 
date, mutations in kinases have been studied in a large variety of cancers (162-164) 
and, correspondingly, kinase inhibitors have emerged a major class of anti-cancer drugs 
that are either in clinical use or in various phases of clinical trials (165-166). In recent 
years, advances in selective enrichment of phosphoproteome have led to systematic 
characterization of aberrantly activated kinase signaling pathways in several cancers. 
Information from such studies is likely to contribute to further development in future 
targeted cancer therapies. Studies describing and using technologies for monitoring 
global phosphorylation events are handled in the section for phosphoproteomics in 
section 1.4.3. 
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1.4 GLOBAL METHODS TO STUDY CELL SIGNALING – THE OMICS 
ERA  
Genomics, proteomics, phosphoproteomics and other omic-based approaches are now 
broadly used in biomedical research to facilitate the understanding of disease 
mechanisms and identification of molecular targets and biomarkers for therapeutic 
and diagnostic development. One important issue which differs between omics-based 
approaches and traditional research is the global and unsupervised strategies. In 
traditional research experiments there is already from the beginning a hypothesis 
involving the outcome of a few known players, this hypothesis is then tested if it is 
valid or not – the experiment is hypothesis driven. In contrast, in omics based 
strategies snap shots of large data sets are compared and the result is used to generate 
a hypothesis about what is ongoing in different situations and the players involved is 
presented by the experiment it self – the experiment is hypothesis generating. 
 
 Biomarkers are referred to as biological entities or characteristics that can be used to 
indicate the states of healthy or diseased cells, tissues, and individuals. Nowadays, 
biomarkers are mostly molecular makers, such as genes, proteins, metabolites, 
glycans, and other molecules, that can be used for disease diagnosis, prognosis, 
prediction of therapeutic responses, as well as therapeutic development (167-169). 
Over the past decade, high-throughput technologies, such as genomic microarrays, 
proteomics and metabolomics by mass spectrometry, have been used to generate large 
amount of data from single experiments that allow for global comparison of changes 
in molecular profiles that underlie particular cellular phenotypes. As a result, the 
omics-based approaches, coupled with computational and bioinformatics methods, 
provide unprecedented opportunities to speed up the biomarker discovery and now 
are widely used to facilitate diagnostic and therapeutic developments for many 
diseases and particularly in cancers (170-177). Potential biomarkers have been 
identified at various molecular levels, including genetic, mRNA, protein/peptide, as 
well as epigenetic (178-180), miRNA (181-182), glycans (183-186), and metabolites 
(169). For example, using DIGE-based proteomics potential biomarkers were 
identified to be useful for the diagnosis of metastatic prostate cancer (187), and a 
proteolytic fragment of alpha1-antitrypsin was identified as a potential diagnostic and 
prognostic marker for inflammatory breast cancer as well as a target for potential 
therapeutic intervention (188-189). In addition, microRNAs, such as miR-500, were 
identified as a potential diagnostic marker for hepatic cell carcinoma (190). 
Increasingly, pathway and network-based analyses are applied to Omics data to gain 
more insight into the underlying biological function and processes, such as cell 
signaling and metabolic pathways and gene regulatory networks (191-192). For 
example, 12 core signaling pathways were shown to be altered in human pancreatic 
cancers through genomic analyses (191). Network modeling linked breast cancer 
susceptibility to the centrosome dysfunction (193), and led to the identification of a 
proliferation/ differentiation switch in cellular networks of multicellular organisms 
(194). These approaches have led to a new trend in identifying biomarkers in recent 
years, namely, pathway and network-based biomarker discovery, which identify  
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panels of, instead of single, biomarkers for practical use in diagnostic and therapeutic 
developments (195-198). Protein networks have been shown to provide a powerful 
source of information for disease classification and to help in predicting disease 
causing genes (199-202). Network approaches have also been used for improving the  
prediction of cancer outcome (203-204), providing novel hypotheses for pathways 
involved in tumor progression (204), and exploring cancer associated genes (205). 
However, while the omics technologies and bioinformatics tools for analyzing omics 
data are rapidly advancing, the functional analysis and interpretation of the data 
remain challenging. 
 
1.4.1 Genomics 
Over recent years the sequencing of the whole genome of different organisms, 
including man, has provided the foundation for several powerful new biotechnologies 
offering insight into the molecular characteristics of the cell, the regulation of cellular 
activity, the response of the cell to its environment and cellular defects in disease states. 
Genomics/transcriptomics are based on the faithful transcription of DNA from the 
coding region of the gene into a complementary single-stranded mRNA molecule and 
subsequent translation into the protein. Application of these technologies were 
revolutionizing the biosciences in the early 2000’s, (206). Functional genomics is being 
used to characterize the molecular events occurring in disease processes (207), to 
identify polymorphisms in genes that may be associated with increased (or decreased) 
risk of specific diseases (208) and to search for biomarkers of disease (209). DNA array 
technology allows the expression of thousands of genes to be analyzed simultaneously. 
This high-throughput approach is facilitating rapid advances in genomics and 
transcriptomics. The principle underlying the array technologies is hybridization 
between complementary single-stranded nucleic acid sequences exploiting the specific 
relationship between A and T, and G and C (210). The latest micro-arrays consist of 
densely-packed spots of single-strand cDNA or oligonucleotides complementary to the 
sequence of the gene of interest immobilized onto a substrate, e.g. glass or 
nitrocellulose. mRNA is extracted from cells, reverse-transcribed using fluorescently-
labelled nucleotides and hybridized to the array. The array is laser-scanned and 
expression levels determined from the intensity of the fluorescence at each spot. The 
results are processed through a database and data mining tools used for analysis (211). 
Such experiments generate massive amounts of expression data, the interpretation of 
which is challenging and depend largely on the quality of genomic databases and of the 
software tools available. Good experimental design and careful attention to 
experimental protocols are critical to the success of micro-array experiments. Lately, 
the development of systematic approaches to identify somatic mutations has prompted 
exhaustive analyses of changes in cancer genomes, including copy-number changes 
(deletions and amplifications of DNA), rearrangements, small insertions and deletions, 
and point mutations (212). Recently, these efforts have culminated in the sequencing of 
complete genomes of human cancers, providing comprehensive catalogues of somatic 
mutations (213-214). These studies have yielded insights into the genes that contribute 
to cellular transformation (212).  
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1.4.2 Proteomics 
The term ‘proteome’ was coined by Marc Wilkins and Keith Williams at the Center 
for Analytical Biotechnology of Macquarie University, Australia in 1995. The word 
is a combination of ‘protein’ and ‘genome,’ and may be defined as the protein 
molecules associated with a genome (215). Proteomics is the study of the various 
types of proteins and their interactions in a cell or other biological entity. It is the 
application of tools from different fields, as diverse as clinical medicine, molecular 
biology, mass spectrometry (MS) and bioinformatics to explore the localization, 
identification and characterization of protein, as well as to shape this  information into 
new knowledge (215). 
 Proteomics, which can be defined as large scale analysis of the whole protein 
complement of e.g. cells and tissues, enables the unbiased comparison of different 
cellular states in biology and medicine at a ‘‘systems-wide’’ level. However, 
technological challenges associated with proteomics have long prevented its full 
potential. Two-dimensional (2D) gel electrophoresis was conceived more than 30 years 
ago (216). This technology has been useful for low-complexity protein mixtures but has 
still not matured into a comprehensive and accurate technology for complex proteomes. 
The introduction of high-sensitivity protein identification by MS was first promising 
also for 2D gel analysis, but in fact it revealed that the thousands of spots seen in the 
gel maps are actually variants of a few hundred of the most abundant proteins (217). A 
few years ago it also became clear that quantification of these proteins is far from 
accurate because of spot overlap (218). Accordingly, ‘‘biomarkers’’ found by these 
technologies tend to be the same regardless of the system under investigation (219).  
MS technology with low resolving power e.g. in the form of surface enhanced lased 
desorption ionization (SELDI), gained a lot of attention among clinicians a few years 
ago. However, from a mass-spectrometric point of view, SELDI boils down to simple 
matrix associated laser desorption ionization (MALDI) spectra of very complex 
mixtures and would be expected to only yield a subset of the most abundant low-mass 
peptides and protein fragments. Such species could still have proven sufficient to 
classify patient samples. Yet, identification of the peaks comprising the SELDI 
patterns, usually turned out to belong to the same nonspecific proteins unlikely to be 
directly associated with the disease. In contrast to the above approaches, which were 
discussed as promising proteomics technologies as late as a few years ago; MS-based 
proteomics has taken great strides in development (220). In particular, technological 
improvements in the last 5 years have dramatically increased the routine availability of 
extremely high-performance MS. In some cases, these technologies already existed but 
could only be applied in specialized situations by expert laboratories and at low 
throughput. Today, MS techniques with high accuracy can be applied in most 
proteomics contexts and comprehensive analysis of complex proteomes is best 
achieved by using high-resolution proteomics technologies. An important aspect of 
MS-based proteomics is the remarkable inroads of proteomics strategies into the 
analysis of phosphorylated proteins. 
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1.4.3 Phosphoproteomics 
In the past, kinases and their activities were generally studied on an individual basis 
using biochemical approaches. However, technological advances in the recent past 
have led to development of several high-throughput strategies to study the 
phosphoproteome. High-throughput technologies for monitoring phosphorylation 
events include array-based technologies such as peptide arrays (221-224), reverse phase 
protein arrays (225), antibody arrays (226) and mass spectrometry (227-231).  
 
The first technique for global analysis of phosphorylated proteins from complex protein 
samples was done by separating the proteins according to their pI and their molecular 
weight using 2-DE (232-236). The separated proteins can subsequently be visualized 
using standard protein stains (e.g., Coomasssie blue and silver staining). By this method 
the post translationally modified proteins, such as phosphoproteins, can appear as 
multiple pI variants according to their modification states, since the addition or 
subtraction of a chemical group can subtly, but detectably, alter the pI of a protein. This 
is especially evident for multiply phosphorylated proteins. Phosphoproteins separated 
by gel electrophoresis can also be visualized by the use of a phosphospecific stain such 
as Pro-Q Diamond (237-241). However, as discussed above, 2D is having a tuff time 
with highly complex samples. On the other hand, ideas originating from 2D by using 
narrow-pH-IPG-strips on the peptide level is showing excellent results and is promising 
also for phosphoproteomics (242-243). Alternatively, phosphoproteins can be 
radioactively labeled using 32P or 33P (237-238) and detected by autoradiography, 
which is the most sensitive method available, but may not be compatible with 
downstream analytical procedures such as MS.  Radioactive labeling is possible both in 
vivo as well as in vitro. In in vivo studies, cells are incubated with 32P, however, the 
presence of endogenous ATP pools within cells can interfere with the incorporation of 
the label and result in inefficient radioactive labeling (244). Furthermore, 32P is toxic 
for many cells and will over time cause damage to the cell. In in vitro studies, proteins 
are incubated with specific kinases in the presence of [g-32P]-ATP, and under 
appropriate conditions 32P is incorporated at the phosphorylated amino acid residue. A 
major drawback of this method, however, is that kinases may phosphorylate target 
proteins promiscuously. The occurrence of promiscuous phosphorylation events is due 
to the unnaturally high concentration of kinase compared to the substrate concentration 
(134), and kinases that would not phosphorylate a particular protein in vivo might still 
induce phosphorylation in vitro (245). 
 
Enricment strategies prior to MS-analyses in phosphoproteomics 
Phosphoproteins are nowadays mostly characterized using MS methods after 
proteolytic processing. However, phosphopeptides are notoriously difficult to analyze 
by MS, especially in the presence of non-modified peptides. This is mainly due to 
lower ionization efficiency of phosphopeptides resulting in lower signal intensities in 
the presence of nonphosphorylated peptide ions. Thus, efficient enrichment of the 
phosphorylated peptides prior to MS analysis will result in increased sensitivity and  
 
 
   21 
more efficient characterization. There are various phosphoproteomic enrichment 
strategies to choose from and the most common is described below. 
 
IMAC 
Imobilized metal affinity chromatography (IMAC) is a widely used affinity based 
technique for enrichment of phosphopeptides prior to MS analysis. Metal ions (Fe3+, 
Al3+, Ga3+, or Co2+) are chelated to nitrilotriacetic acid (NTA) or iminodiacetic acid 
(IDA) coated beads, forming a stationary phase to which negatively charged 
phosphopeptides in a mobile phase can bind. The technique was initially used for the 
affinity-purification of proteins based on the interactions of histidine and cysteine 
residues with the IMAC resin (246-248). However, the binding of phosphoproteins and 
phosphoamino acids to metal ions, first demonstrated by Andersson and Porath in 1986 
(249) , gave the technique new potential. IMAC was further extended by Neville et al. 
to the enrichment of phosphopeptides obtained from proteolytically digested proteins 
(250), and the IMAC technique has since been used extensively for enrichment of 
phosphopeptides prior to MS analysis (251-256). One of the problems associated with 
the IMAC technique is the often high level of nonspecific binding when used for 
phosphopeptide enrichment of highly complex peptide samples. Nonphosphorylated 
peptides containing multiple acidic amino acid residues co-purify with the 
phosphopeptides, thereby reducing the selectivity of the method. This is a serious 
problem, due to the more efficient ionization of nonphosphorylated peptides in 
subsequent MS analyses resulting in the suppression of signals from phosphopeptides. 
Ficarro and co-workers circumvented this problem by derivatizing the carboxylic 
groups on acidic amino acid residues in peptides by O methyl esterfication (257) and 
thereby improving phosphopeptide enrichment considerably (257-258). However, 
further experiments have shown that Omethyl esterification does not derivatize 100% 
of the available carboxylic acid groups, and that it can increase the complexity of the 
analysis due to signals originating from peptides with different degrees of O-
methylation (259). Another approach to increase the efficiency of IMAC is to adjust the 
pH. Acidification of a sample prior to IMAC analysis protonates the carboxyl groups 
on the highly acidic amino acid residues and reduces nonspecific binding. In most 
studies, 0.1–0.25 M acetic acid (pH ,2.7) were used as a loading buffer for IMAC, but it 
has been shown that the pKa value of phosphoric acid decreased to 1.1 upon 
methylation. The pKa values of phosphopeptides would therefore be expected to be 
significantly lower than that of phosphoric acid due to the organic environment 
provided by the surrounding amino acid residues. By decrease in the pH of the IMAC 
loading conditions further (below pH 1.9), more acidic peptides will become 
neutralized while phosphopeptides will retain their negative charge and their binding 
affinity toward the IMAC resin. Kokubu and co-workers showed that 0.1% 
triflouracetic acid (TFA), 50% ACN as IMAC loading buffer reduced the level of 
nonspecific binding and improved the specificity of the method toward 
phosphopeptides (260). Yet another approach to improve the performance of IMAC is 
to reduce the complexity of the peptide samples by prefractionation using methods such 
as IEF (261-262), Ion Exchange Chromatography (263) or hydrophilic interaction 
chromatography (HILIC) (264) prior to IMAC purification. 
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TiO2 
In the mid-2000s TiO2 chromatography was introduced as an alternative to IMAC.  In 
2004, Pinkse and co-workers presented an online 2-D LC strategy for phosphopeptide 
analysis with spherical particles of titanium dioxide (Titansphere) as the first dimension 
and RP material as the second dimension. The peptide sample was loaded onto TiO2 
columns in 0.25 M acetic acid (pH 2.9), which promoted the binding of 
phosphopeptides. Unbound, nonphosphorylated peptides were trapped on the RP 
column, and subsequently eluted and analyzed using nanoLC-ESI-MS/MS. The 
phosphopeptides were eluted from the TiO2 column using an alkaline buffer (pH 9.0), 
concentrated on the RP precolumn and analyzed using nanoLC-ESI-MS/MS (265) . 
The strategy was tested on a 153 kDa homo-dimeric cGMP-dependent protein kinase, 
and eight phosphorylation sites were identified, including two novel sites(265). A 
protocol for phosphopeptide enrichment using TiO2 has been developed by the protein 
research group in Odense. In this offline strategy peptide loading is performed at highly 
acidic loading conditions using various substituted organic acids including 2.5-
dihydroxybenzoic acid (DHB), phthalic acid or glycolic acid to efficiently eliminate 
binding of acidic peptides to the TiO2 resin (266-268). In addition, by increasing pH of 
the elution buffer from 9.0 to 11.3 (using ammonia solution), phospho peptides are 
more efficiently eluted from the TiO2 resin, resulting in increased sensitivity (267). 
TiO2-chromatography provides a high selectivity toward phosphopeptides in the 
optimized loading buffer and the offline setup is simple, fast, and does not require 
expensive equipment. Furthermore, TiO2 is extremely tolerant toward most buffers and 
salts used in biochemistry and cell biology laboratories (266).  
 
Combining SCX and downstream enrichment strategies 
Strong cation exchange (SCX) was originally used for prefractionation of proteins and 
peptides, where positively charged groups (cations) interact with negatively charged 
functional groups on the SCX particles. In 2004, Beausoleil and co-workers introduced 
the use of SCX for phosphopeptide enrichment (263). Tryptic peptides were acidified 
in 5 mM KH2PO4, 30% ACN, pH 2.7. At this pH many tryptic peptides will have a 
charge state of 12 due to the charge at the C-terminal arginine or lysine as well as the 
charge on their N-terminus. Tryptic mono-phosphorylated peptides carrying the 
negative charge from a phosphate group would therefore have a net charge of 11 at pH 
2.7. Phosphopeptides were therefore expected to display weakened binding to SCX 
material, and therefore elute before nonphosphorylated peptides with multiple positive 
charges. Multiply phosphorylated peptides would have net charges at 0, and would 
therefore not be retained by the SCX material. However, in this particular study, the 
authors did not examine the unbound peptides in the SCX flow-through. Bound tryptic 
peptides were separated by SCX chromatography using a gradient of KCl and finally an 
elution step using pH 7.0. The early eluting peptides were desalted and analyzed by RP 
LC-MS/MS. Their results confirmed a high level of phosphopeptides in the early 
fractions, which had been separated from nonphosphorylated peptides found in later 
fractions. Beausoleil et al. identified 2 000 phosphorylation sites from 8 mg nuclear 
extract of HeLa cell lysate using this approach (263). For large-scale phosphoproteomic 
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studies, SCX is most efficient as a prefractionation technique prior to phosphopeptide 
enrichment using either IMAC or TiO2 chromatography. Trinidad and co-workers 
compared the enrichment efficiency of SCX as a prefractionation method prior to 
IMAC to both IMAC and SCX alone (263). They found that the combination of SCX 
and IMAC led to at least a three-fold increase in the number of phosphopeptides 
identified relative to either approach alone. In addition, a work by Villén et al. in which 
they fractionated tryptic digests from murine liver using SCX and enriched all 15 
fractions for phosphopeptides using IMAC,  showed that phosphopeptides were spread 
throughout all SCX fractions (269). Neverthless, SCX greatly improves 
phosphopeptide recovery when used as prefractionation prior to subsequent 
phosphopeptide enrichment and robust protocols for such studies are now available to 
the scientific community (270). Using a combination of SCX and IMAC, Gruhler et al. 
performed a large-scale phosphoproteomic study on the yeast pheromone signaling 
pathway and identified and quantified more than 700 phosphopeptides (252). Another 
study from Olsen et al found 2 244 phosphorylated proteins in HeLa cells upon 
stimulation using EGF by combining SCX and TiO2 chromatography (271). Anyhow, it 
should be noted that in both cases large amounts of starting material were used and it 
remains to be determined whether the combination of prefractionation and enrichment 
will be ideal for very low microgram levels of starting protein. Finally, the leading 
study with regard to phosphoproteomics also uses SCX in combination to IMAC and 
TiO2 and was presented recently by Olsen and Mann, reporting the impressive number 
of more than 6000 phosphorylated proteins in their study describing phosphorylation 
events during mitosis (272). 
 
Interpretation of phosphoproteomic experiments - the importance of sharing data 
Even though phosphoproteomic studies really have started to pay off in numbers, the 
knowledge of the phosphorylated sites per se is neither sufficient to identify how 
signals are propagated into cells nor adequate to define the complexity of the 
intracellular networks. To fully appreciate the relevance of phosphoproteomic 
approaches it is essential to gain additional knowledge about the biological conditions 
under which the phosphorylation occurs, to identify the enzymes (kinases and 
phosphatases) that switch ‘on and off’ their substrates, and to understand the functional 
consequences that these modification events have on cellular processes. Since the future 
knowledge and exploitation of reversible phosphorylation relies on the accessibility of 
the data, it is of fundamental importance to develop and maintain public depositories to 
facilitate shared data retrieval. Bioinformatics resources which also incorporate 
substantial phosphorylation data are PHOSIDA (273-274) and phosphoPEP (275) 
which are specialized in annotation of large-scale experiments. Additional information 
on phosphorylation resources can be found at the Phospho.ELM link page 
(http://phospho.embl.de/linkshtml). 
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2 THE PRESTENT STUDY 
 
2.1 AIMS 
The general aim of this thesis was to set up and use unsupervised global methods to 
gain novel insight of cellular signaling events responsible for the mechanisms 
controlling radio resistance in NSCLC cells. The aim was further to use such 
information to generate hypothesis and find candidates that could be sent on to future 
pre-clinical evaluation in larger cohorts of cell lines and optimally also to future clinical 
intervention.  
 
The specific aims were: 
 
Paper I: To use quantitative proteomics and a novel pathway search engine (PSE) to 
find differences on the pathway level when NSCLC cells are irradiated with low – and 
high LET IR. 
 
Paper II: To globally screen for genes of importance for the increased cell death 
observed in NSCLC cells when combining conventional IR and the Staurosporine 
analouge, PKC412. In addition, to further evaluate the cellular impact of such 
gen/genes. 
 
Paper III: To set up a method for phosphoproteomic profiling of complex samples. 
Moreover, to use this method to explore signaling events in NSCLC cells controlled by 
ephrin B3 (ephrin B3 was a found to be of importance for mechanisms of radio 
resistance in Paper II). 
 
Paper IV: To further explore the signaling question regarding differential apoptotic 
response to low and high LET IR (Paper I) in NSCLC cells by using the approach of 
the phosphoproteomic set up in Paper III. 
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2.2 MATERIAL AND METHODS 
All material and methods used in paper I-IV are described in each paper and/or in their 
corresponding references. A brief description and comments are presented below. 
  
2.2.1  U-1810 cells as a model system to study radioresistance 
mechanisms of NSCLC 
In all of the studies (Paper I - IV) of this thesis, the NSCLC cell line U-1810 was used 
as model system to study mechanisms of resistance towards conventional low LET 
radiation. U-1810 cells were characterized by Berg et al at the department of Oncology 
at Uppsala Academic Hospital in Sweden (276). Accordingly, the” U” in U-1810 
stands for Uppsala. U-1810 cells were derived from a patient with undifferentiated 
large cell carcinoma and are classified as adherent as they grow attached to the flasks. 
One way of characterize the radio sensitivity or how resistant a cell line is to radio 
therapy is to use clonogenic survival assay to calculate its SF2 value (277). The SF2 
value is equal to the mean survival fraction after cells have been irradiated with 2Gy, 
where the value of 1.0 means that all cells have survived. U-1810 cells are deficient in 
p53 and show a high degree of radioresistance with a SF2 value of 0.88. Moreover, U-
1810 cells could be stated to have a high proliferation rate relative to other lung cancer 
cell lines. Thus, it was considered as a good model system for method development and 
for studying mechanisms of radioresistance in NSCLC.  
 
2.2.2 Low - and high LET irradiation 
Low LET IR delivered as photons of gamma rays using a 60Co source (LET= 3 
KeV/μm, absorbed dose 8 Gy) was used in Paper I, Paper II and Paper IV and is, as 
indicated in the section for radiotherapy in the introduction, the quality of radiation that 
is commonly used in the clinic for cancer therapy; hence it is characterized as 
conventional radiotherapy.  Whenever we are referring to only IR without stating the 
quality of IR in the text of this thesis, we are referring to low LET IR. High LET IR 
was used in Paper I and Paper IV and in the form of accelerated nitrogen ions 
(LET=125 KeV/μm, absorbed dose 4 Gy). The 4N7+ ions were delivered with a mean 
energy of 20.9 MeV/nucleon from the Gustaf Werner synchrocyclotrone at the 
Svedberg Laboratory, Uppsala University, Sweden. 
 
2.2.3 RNA interference 
Small RNA molecules called siRNA (short interference RNA) is short single stranded 
RNA oligo nucleotide strands consisting of 20-22 nucleotides, binding specifically to 
sequences of mRNA. As a result of the binding, the mRNA is rapidly digested and 
cannot be expressed. However, to achieve robust gene silencing, experimental 
conditions need to be carefully optimized for each gene/protein to be silenced and 
every different cell line to be used. The siRNA technique was used to silence ephrin B3 
in Paper II and Paper III. Custom made ephrin B3 siRNA was purchased from 
Qiagen (Qiagen, Maryland, USA). One potential problem with siRNA technology is 
the off target effects in which a design siRNA in addition to inhibit its target also  
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blocks the expression of other proteins making the biological implementation of results 
difficult. To avoid this in our studies, we used the 5’-CCAGGAGTATAGCCCTAAT-
3´ sequence since it was previously described as unique relative to other Ephrin 
members (278). Transfections were performed according to the manufacturers’ 
instructions. Briefly, 500,000 cells were seeded onto 10 cm dishes and transfected 
after 6 h using 100 nM siRNA. 
 
2.2.4 Assays of cell fate 
Growth 
Cell division was assessed in Paper II using the CFSE labeling method. The CFSE is 
a cell-permeable molecule which is non-fluorescent until it is cleaved by intracellular 
esterases to yield the fluorescent carboxyfluorescein succinimidyl ester (CFSE), 
which is retained within the cells. During each cell division, the fluorescent label will 
be progressively diluted, allowing cell proliferation to be monitored by Fluorescence 
Associated Cell Sorting (FACS) (279). 
 
Apoptosis and mitotic catastrophe 
To asses if cells were dying from apoptosis or mitotic catastrophe the characteristics of 
nuclear morphology typical for each state was analyzed in Paper II. Cells were fixed 
and the nuclei were stained with mounting media containing 4,6´diamidino-2 
phenylindole (DAPI). The number of cells with nuclear morphology indicative of an 
apoptotic or mitotic cell was quantified using a fluorescent microscope. Another 
strategy to measure apoptosis was the solid-phase sandwich enzyme immunoassay 
M30-Apopotosense™ ELISA in Paper IV. In this assay, apoptosis is detected as 
caspase-mediated cleavage of cytokeratin 18 by the M30 monoclonal antibody which 
specifically recognize a neo epitope exposed in caspase-cleaved cytokeratin 18 (280). 
Also, Caspase-3 activity was examined in Paper I in intact cells using an antibody 
that recognizes active caspase-3 as an indication of apoptosis. 
 
Senescence 
NSCLC cells were analyzed in Paper II using a commercial Senescence Cells 
Histochemical Staining Kit where the cells are stained with X-gal-based staining 
mixture overnight at 37 °C. The percentage of blue-stained cells expressing β-
galactosidase was then examined in a microscope. 
 
2.2.5 Gene array 
In paper II, the method for global analysis was on the level of expressed genes and 
data was acquired from gene array. The mRNA was isolated from 10 million U-1810 
cells/ treatment and RNA purity and concentration were assessed using a NanoDrop 
ND-1000 UV-Vis Spectrophotometer. Gene expression analyses were performed using 
Affymetrx chip on the Affymetrix platform (Affymetrix Inc, CA, USA). The principle 
was to synthesize cDNA from the mRNA and then cRNA from the synthesized DNA. 
Samples are labeled with a fluorophore and if the nucleic acid sequences on the probe  
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of the array match the sample hybridization occur. It generates a signal that depends on 
the strength of the hybridization determined by the number of paired bases, thereby  
reflecting the degree of mRNA expression. The synthesis of cRNA, labeling and 
hybridization were performed according to the protocols provided by the manufacturer.  
 
2.2.6 Enrichment of phosphorylated peptides using SCX-fractionation 
and TiO2-magnetic beads 
In Paper III and IV a phosphoproteomic approach was applied, thus requiring 
strategies to enrich for phosphorylated peptides before sending the samples to analysis 
in the mass spectrometer. This is required basically because of the low abundance of 
phosphorylated peptides compared to the non phosphorylated peptides. The enrichment 
of our complex samples was performed in two steps, where step one was SCX-
fractionation inspired by the protocol of Villen et al., (270) where the peptides are 
fractionated depending on their net charge. Peptides with low positive net charge elute 
early.  Each sample was manually injected into the loop; an Agilent 1200 LC system 
was used, complete with binary pump, diode array detector and fraction collector.   
Samples were fractionated into 12 fractions per run and identical fractions from the 
three runs per sample were then pooled before cleanup.  
 
The second step of enrichment was performed by taking advantage of the affinity of 
the negative phosphate group/s to positive Titanium charges. After clean up, each 
fraction from SCX fractionation was resuspended in binding buffer (80 % ACN, 5 % 
TFA and 1M Glucolic Acid). TiO2 magnetic beads TiO2 (Mag Sepharose™, GE 
Healthcare) were used for enrichment of phosphopeptides. In this process, peptides are 
bound to the beads, beads are washed from non bounding peptides, the flowthrough is 
put on new beads for a second chance of binding before extensive washing steps and 
final elution steps in Amonia-based basic buffer (pH > 11). All wash steps and elutions 
were done by pipeting the solvents while the tubes where in a magnetic tube rack where 
beads were allowed to congregate at the magnet for one minute before collecting the 
supernatant, an approach that was convenient and highly simplifying the handling of 
the beads. More detailed aspects regarding global studies of protein phosphorylations 
are conversed in the section for discussion. 
  
2.2.7 LTQ-FT mass spectrometry 
For the mass spectrometry (MS) analysis in Paper I, a 7-Tesla hybrid linear ion trap 
Fourier transform mass spectrometer (LTQ FT) equipped with a Proxeon 
nanoelectrospray ion source was used. For separation of the peptides, a high 
performance liquid chromatography setup, Agilent 1100 nanoflow system, was applied. 
As analytical column, a 15 cm long fused silica emitter was used. The column was 
packed in house from a slurry of reverse phase material in methanol. The peptide 
solution was loaded onto the analytical column and for data acquisition unattended 
mode was used in which the mass spectrometer automatically alternated between a high  
resolution overview MS-scan and a lower resolution fragmentation scan (ECD 
followed by CAD) of the two most abundant peptides at any given moment. 
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2.2.8 LTQ - Orbitrap Velos mass spectrometry 
For phosphoproteomic analyses in Paper III and IV each fraction from a sample 
enriched for phosphopeptides was injected into online HPLC-MS performed on a 
hybrid LTQ-Orbitrap Velos mass spectrometer. An Agilent HPLC 1200 system was 
used to provide the gradient for online reversed-phase nano-LC. The sample was 
injected into a C18 guard desalting column prior to a C18 picofrit column  installed on 
to the nano electrospray ionisation source of the Orbitrap Velos instrument. Acquisition 
proceeded in ~3.5s scan cycles, starting by a single full scan MS, followed by two 
stages of data-dependent tandem MS: the top 5 ions from the full scan MS were 
selected firstly for collision induced dissociation (CID) with MS/MS detection in the 
ion trap, and finally for higher energy collision dissociation (HCD) with MS/MS 
detection in the orbitrap (FTMS). Additional experiments were performed using 
electron transfer dissociation (ETD), as an alternative fragmentation method for peptide 
ions 
 
2.2.9 Data handling and validation 
Subsequent to gene array analysis performed in paper II, the data were analyzed by the 
GeneSpring GX software (Agilent Technologies, CA, USA). Normalization of gene 
expression data was accomplished in two ways: per chip normalization and per gene 
normalization. For per chip normalization, all expression data on a chip were 
normalized to the 50th percentile of all values on that chip. For per gene normalization, 
the data for a given gene was normalized to the median expression level of that gene 
across all samples. The expression profiles from the three independent experiments 
were compared using ANOVA (parametric test, variances assumed equal) to identify 
genes that were differentially expressed between the different treatments. A few 
selected genes were the validated on real time quantitative PCR (RT-qPCR) to confirm 
expression pattern from gene array analyses. Further analyses of gene ontology were 
also done using the GeneSpring GX software. For pathway analysis of proteomic data 
in Paper I, a novel pathway search engine (PSE) developed by the group of Roman 
Zubarev (281) was applied. This search engine allows identified proteins to connect to 
key nodes which receive a score due to its connectivity with the proteins. Top scoring 
key nodes is then mapped to corresponding genes which in turned are mapped on 
pathways in the Transpath data base. In paper III and IV Protein Center 
(PROXEON/Thermo Fisher Scientific) were used to handle and filter phosphorylated 
peptides and proteins as well as visualize phosphorylation sites. Ingenuity pathway 
analysis (Ingenuity Systems, Inc., Redwood city, California, USA) was used to 
generate hypothesis for biological interpretation by creating networks and map 
differentially phosphorylated proteins on canonical pathways.For validation of 
hypotheses generated from omics data and subsequent interpretation of the data using 
bioinformaic tools, orthogonal strategies using siRNA (described above), standard 
immunobased assays like western blots, immuno precipitation, ELISA and 
immunofluorescence analysis were used. In addition, for validation of biological 
function in Paper I pharmacological inhibitors of JNK and p38MAPK were applied to 
ascertain the role of these kinases in high LET IR-induced apoptotic signaling.  
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2.3 RESULTS 
2.3.1 Paper I 
Proteomics and Pathway Analysis Identifies JNK-signaling as Critical for High-LET 
Radiation-induced Apoptosis in Non-Small Lung Cancer Cells 
 
The aim of this study was to, by an approach of quantitative proteomics, gain insight of 
which pathways that are critical for induction of apoptosis by high LET IR. The 
NSCLC cell line U-1810 which is highly resistant to conventional low LET IR and also 
has impaired low LET IR-induced apoptotic signaling (65) was shown as sensitive to 
high LET IR by induction of apoptosis.  In response to high LET but not low LET IR, 
these cells showed a time-dependent increase in apoptotic morphology. Moreover a 
time-dependent increase in activation of caspase-3, one of the major executor caspases 
in apoptotic signaling, was observed after high LET IR. In accordance with previous 
results from our research group (65), little or no increase in caspase-3 activity was 
observed in response to low LET IR in these NSCLC cells. Thus, the U-1810 cell line 
could be considered as a suitable model system for the study. 
 
We here employed an unsupervised shotgun proteomics approach where Fourier 
transform mass spectrometry coupled to nanoflow-liquid chromatography determined 
the identity and relative abundance of expressed proteins. The development in different 
global proteomic methods have increased the generation of large proteomic data sets. In 
order to extract the most critical signaling events from such large data sets in a non-
biased way, computerized methods based on statistics are required. The Pathway search 
engine (PSE) has been developed as a novel tool intended to meet these requirements 
and its application was used for the first time in this study. Based on the proteomics 
data, PSE suggested the JNK-pathway as a key event in response to high-LET IR. In 
addition, the Fas-pathway was reported activated and the p38- pathway was found 
deactivated compared to untreated cells. Immuno-based analyses (western blot and 
immunofluorescence analysis) confirmed that high-LET IR caused an increase in 
phosphorylation of JNK. Also, more players of the JNK-pathway as it is defined in the 
TRANSPATH database, i.e. MKK4 and 14-3-3α, were proven to be regulated. 
Moreover, pharmacological inhibition of JNK blocked high-LET IR induced apoptotic 
signaling as measured by decreased caspase-3 activation and apoptotic morphology. In 
contrast, neither an activation of p38 nor a role for p38 in high-LET IR induced 
apoptotic signaling was found. Thus PSE predictions were largely confirmed and it was 
proven that PSE could be useful as a hypothesis-generating tool.      
 
2.3.2 Paper II 
Global gene analysis reveals ephrin B3 as a major player in mechanisms controlling 
radioresistance in non-small cell lung carcinoma cells 
The staurosporine analogue PKC 412, but not Ro 31-8220, had previously been shown 
to sensitize NSCLC cells to ionizing radiation (IR) (77, 83). These effect of combining 
PKC 412 and IR was indeed confirmed in this study as an increased caspase-3 activity 
was documented using PARP and cytokeratin 18 cleavage as endpoints. Interestingly 
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we also observed a striking change in the morphology of the cells as they become 
elongated, significantly larger and flattened. To reveal genes of importance for the 
radiosensitizing effect of PKC 412, a total gene profiling in response to co-administration of  i) PKC 412 
with IR and ii) Ro 31-8220 with IR, was implemented using the Affymetrix gene array platform. The 
death increasing combination of IR and PKC 412 specifically caused upregulation of 140 genes and 
down-regulation of 253 genes.  
 
A few genes were selected and verified by real-time quantitative PCR. Out of these, 
suppressed ephrin B3 expression was suggested as a possible radiosensitizing 
mechanism of PKC 412. Silencing of ephrin B3 using siRNA resulted in a decrease in 
cell proliferation, induction of an elongated cell phenotype similar to the phenotype we 
had observed on cells treated with the combination of PKC 412 and IR as well as an 
increase in cell death, measured by quantifying PARP cleavage on western blot and by 
induction of apoptotic cell nuclear morphology. Moreover, silencing of ephrin B3 in 
combination with IR caused a decrease in IR-mediated G2 cell cycle arrest and induced 
cellular senescence illustrated by increased β-galactosidase staining as well as the 
characteristic flattened and elongated cellular phenotype in addition to increase of cells 
in the G0/G1 phase of the cell cycle. Using western blotting an inhibition of the 
MAPKs ERK and p38 phosphorylation and up regulation of p27 was observed. In 
conclusion, our non-supervised approach identified ephrin B3 as a putative signaling 
molecule involved in resistance to conventional radiotherapy.   
 
2.3.3 Paper III 
Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-
survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor 
In paper II we identified ephrin B3 as a critical signaling molecule mediating 
radioresistance of NSCLC cells. Following up on these results, we in this paper aimed 
to understand how silencing of ephrin B3 influenced the phosphoproteome and thereby 
the signalome of these NSCLC cells. For this purpose ephrin B3 expression was 
silenced in the non small cell lung carcinoma cells U-1810 using siRNA.  Cellular 
extracts were generated from these siRNA ephrin B3 silenced cells and non-targeting 
siRNA was used as control. 
 
 One of the main aims of this thesis was to set up a robust global method for analyses of 
the phosphoproteome of complex samples. The method was used in this project and we 
applied a phosphoproteomic approach to perform a global and unsupervised screen for 
changes in the phosphoproteome between U-1810 cells with or without silenced Ephrin 
B3. The workflow consisted of cell lysis, protein digestion, SCX-fractionation (as a 
first separation and phosphopeptide enrichment step) and finally, before mass 
spectrometry analysis, an enrichment of phosphorylated peptides using magnetic 
titanium dioxide beads.  
 
In total, 1083 phosphorylated proteins were identified. Out of these, 150 and 66 
proteins respectively were identified and characterized as only being phosphorylated in 
U-1810 cells treated with non target siRNA versus cells treated with siRNA for Ephrin 
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B3. Network analysis by the Ingenuity software was used to elucidate these data and a 
few candidates from the top network were selected for further studies. Interestingly, 
another ephrin-family member, i.e. the EphA2 receptor B3 together with activation of 
Focal adhesion kinase 1 (FAK1) was reported as a top candidates, activated only in the 
presence of Ephrin B3. 
 
The EphA2 was phosphorylated on Ser 897 only in the presence of ephrin B3, a 
phosphorylation which is known to take place only in absence of the EphA2 ligand 
ephrin A1(282). This phosphorylation is generated by Akt1 (282) which in turn is 
activated by CK2 on Ser 129 (283). Also HSP90AA1 is activated by CK2 and has been 
reported to stabilize EphA2 and save it from degradation (284). These results reported 
in the literature fitted well with our data of the identified phosphorylation sites which 
only were phosphorylated in presence of ephrin B3. In line which such a hypothesis, 
we could also prove in this study that EphA2 actually not existed in these cells when 
ephrin B3 is absent, supporting its degradation when not chaperoned by HSP90AA1. 
By stepwise pathway walking and validation of phosphorylation sites by immune-based 
strategies, this signaling scenario was largely confirmed and our data support an ephrin 
B3/EphA2 survival pathway which potentially is critical for retaining resistance 
mechanisms in NSCLC cells. 
 
2.3.4 Paper IV 
Phosphoproteomic profiling to explore differences in cellular response between high 
and low LET irradiated Non small cell lung cancer cells 
The present study is from a biological perspective a follow up on Paper I as we 
intended to further explore how the signalome differs in response to low vs. high LET 
IR. However, from a technical perspective study IV is rather a follow up on Paper III. 
Thus, we applied the phosphoproteomic approach for profiling, using basically the 
same method as applied in Paper III. 
 
To confirm that our biological system from paper I was still valid i.e. to confirm that 
high LET IR induced apoptosis in the U-1810 cells, we checked activation of the 
proapoptotic BAK and BAX mitochondrial proteins. Indeed we could clearly detect 
BAK and BAX activation in response to high LET IR which was in marked contrast to 
the failure of activation found after low LET IR (65).  
 
In this project, the depth of the identified phosphoproteme were even larger compared 
to our previous study (Paper II). In total, as much as 12012 phosphorylated peptides 
were identified. In addition 1781 other non-phosphorylated peptides also mapping to 
the same proteins as the phosphorylated peptides were identified. This corresponded to 
a total of 2314 unique phosphorylated proteins, thus, reaching numbers of identified 
phosphorylated proteins in the same range as world leading phosphoproteomic 
laboratories (265, 285). Out of those, in a first step of pathway analysis, only 
phosphorylated proteins that were detected in all three replicates corresponding to a 
certain treatment i.e. low or high LET IR but never detected in the comparative 
treatment were send to pathway analysis (low LET IR: 242 phosphorylated proteins, 
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high LET IR:128 phosphorylated proteins). Using this strategy, IPA canonical pathway 
analysis suggested pathways describing assembly of RNA polymerase III complex and 
eIF-signaling only in response to low LET IR. After selection of these two pathways 
which both are implemented in protein synthesis, a more allowing step was added to 
pathway analysis. This second step was added as a strategy to take advantage of as 
much as possible of the information available from the data sets and thereby increase 
coverage of the two pathways of interest from step 1. Hence, the requirement for a 
phosphorylated protein to participate in the second part of pathway analysis was that it 
had to be significantly identified only in at least one of the three replicates 
corresponding to a certain treatment i.e. low or high LET IR but of course still never 
detected in any of the replicates of the comparative treatment. These requirements were 
fulfilled for 823 phosphorylated proteins in response to low LET IR and 431 
phosphorylated proteins in response to high LET IR.  By adding the second layer of 
data, the coverage of the pathways describing assembly of RNA polymerase III 
complex and eIF-signaling which were found activated only in response to low LET IR 
were increased and the data covered a majority of the circuits of these canonical 
pathways.  
 
U-1810 cells are resistant to low LET IR but respond to high LET by induction of 
apoptosis. Thus, NSCLC cells irradiated by low LET IR most probably have higher 
proliferation rate than cells irradiated by high LET IR. As a consequence of higher 
proliferation rate, our finding of increased active protein synthesis which indeed is a 
requirement for speeding up proliferation could be considered as logic since such a 
property undoubtedly would be beneficial for NSCLC cells to resist conventional 
radiotherapy. However, the detailed regulations of the pathways operated by the 
specific phosphorylation sites and upstream kinases await further validation before 
more sophisticated conclusions can be drawn.  
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2.4 GENERAL DISCUSSION 
2.4.1 Methodological and technical perspectives 
Some aspects of using cell lines 
The NSCLC cell line U-1810 is highly radioresistant (65, 77, 82-83, 286), which is 
further described in the method section. This cell line has been used as model system in 
all studies (paper I, paper II, paper III and paper IV) of this thesis, with the aim to 
gain novel insight of the mechanism that control radioresistance in NSCLC.  When the 
final goal of a study is to improve lung cancer therapy one may of course ask why not 
all studies use clinical material or at least living animals like rats or mice. Is it really 
likely that what we can identify as critical signaling networks in tumor cell line can be 
translated into important signaling hubs driving tumors of lung cancer patients? It is of 
course true that it is beneficial to perform research for improved cancer therapeutics on 
clinical material or on animals carrying tumors.  However, the advantages for using cell 
lines and perform preclinical studies are several. For example, it is important to realize 
that in science there is a lot of unknown parameters, leading to the fact that unexpected 
situations continuously happen. - This is true for all studies that require some kind of 
method development and not least in a field of research as young as proteomics and 
phosphoproteomics such as those included in this thesis. Other situations are when 
using unsecure tools, like for example assays that involves antibodies or siRNA’s, there 
is no quality guarantee and the quality of such tools can vary even from batch to batch.  
When setting up and optimizing new methods it is likely that experiments will fail 
several times both because of unpredicted chemical and biological reactions as well as 
simple laborative mistakes. In these situations, the use of a cell line model that is easy 
to maintain is optimal. One other advantage is also that when the method finally is 
working and the reagents involved have been tested and quality secured, it is easy to set 
up several independent experiments to check the robustness of the method. This thesis 
uses omics methods and one critical step is to interpret the output data of the 
experiment. Also this step is usually much easier when using cell lines, since you avoid 
the obvious complexity of having different individuals which all have their individual 
genomes and proteomes which differs by definition. The existing bio banks of clinical 
material are due to years of hard work and are of course precious and extremely 
valuable in the work of finding new cancer therapeutics. Moreover, albeit there are 
biobanks of clinical tumor materials these are of much greater complexity as they 
contained interindividual changes in the proteome which might be a confounding factor 
when to discover the important signalling aberrations within a given tumor type. 
Therefore, it is important to establish robust methods first, preferably using cell lines 
and then animals, before running the experiments also on clinical material. One 
alternative strategy for biomarker discovery or for identification of targets with 
therapeutic potential could be to run omics methods first on cell lines and maybe also 
on animals to generate hypotheses, which are first validated on the same material and in 
the end, only perform hypothesis driven validation on clinical material. Thereby 
avoiding the use of large amounts of clinical material and also circumvents some of the 
difficulties with fluctuations among individuals. 
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Workflow for signalomics experiments 
Taking the structure of all four projects in the thesis into account, a general workflow 
for signalomics can be created by gathering their common principles. The first step in 
this workflow was to define the samples to be compared and to prove that there were 
parameters that differs between them, thereby justifying the likelihood of finding 
differences also in the cellular signaling responsible for such events. In this thesis all 
the studies were using situations were a certain treatment forced the radioresistant U-
1810 cells to somehow increase death while the control treatment did not. However, the 
same workflow can of course be used also for any other comparative situations. A 
schematic illustration of such general workflow for signalomics experiment is 
described in figure 7. 
 
 In Paper I we compared non-irradiated, low LET and high LET irradiated NSCLC 
cells, and the fact that high LET IR increased apoptotic signaling was proven by 
increased apoptotic morphology as well as increased caspase 3 activation. The 
comparison between low and high LET IR was made also in Paper IV and here the 
increase of apoptotic signaling in response to high LET IR was confirmed by increased 
activation of mitochondria by activation of the pro-apoptotic BAK and BAX proteins 
observed by two different methods. In Paper II the comparison was between genes 
that were specifically up and down regulated for samples treated with the combination 
of IR and RO-3182 and samples treated with IR and PKC 412. Hence, genes regulated 
in untreated samples or in samples only receiving IR or either of the PKC inhibitors 
alone were excluded during data filtering. The cellular effect of combining IR and PKC 
412 were striking by a pronounced effect on cellular morphology as well as, PARP 
cleavage and CK18 cleavage. Finally, in paper III, we were comparing control cells 
and cells with silenced ephrin B3. This was due to results from Paper II and the 
cellular effects of silencing ephrin B3 were confirmed by the clear changes in cellular 
morphology having a similar appearance as in Paper II. 
 
For sample preparation prior to proteomics experiment we were using a buffer based on 
strong concentrations of UREA for cell lysis, protease and phosphatase inhibitor tablets 
were always added, however, they were probably not necessary as the detergent will 
most probably immediately denature all proteases and phopshatases. For genomics 
experiment, cells were lyzed in a commercial lysis buffer from Sigma Aldrich. 
Different amount of material were required depending on the analysis. For example 
about 10 million cells were needed for genomic experiments, while hundreds of 
millions of cells were used for the phosphoproteomic experiments.  When proper and 
equal amounts of material for each comparable set of samples have been prepared 
different procedures follows. These are dependent of the purpose of the analysis e.g. 
extracting mRNA and synthesizing DNA and cRNA for genomics or digestion of 
proteins to peptides for shutgun proteomics, in case of phosphoproteomics also further 
fractionation steps and enriching strategies had to be done (see separate aspects of 
phosphoproteomics below). 
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 Next, follows the step of omics data collection. In the genomics experiments in Paper 
II we used the Gene Array platform from Affymetrix to globally measure gene 
expression. For proteomics experiments in Paper I a LTQ-FT mass spectrometer were 
used and for phosphoproteomics experiments in Paper III and IV we used an Orbitrap 
Velos mass spectrometer. With regard to the phosphoproteomics experiment, several 
different types of mass spectrometers were tried out, however, only the Orbitrap Velos 
managed to identify a satisfying number of phosphorylated proteins. Yet, this is most 
likely not only due to the higher resolution per se, but to differences in fragmentation 
techniques and the increased detection sensitivity of this instrument.  
 
After collecting the data, during data analysis, there are several different bioinformatic 
tools that can be used. For genomics experiments, we applied Gene spring (Paper II). 
In Paper III and IV, Protein Center was used to sort phosphorylated peptides from non 
phosphorylated ones. In fact Protein Center was to our knowledge the only commercial 
software were modified proteins could easily be imported from Proteome Discoverer 
without any manual changes of the sequences, something that dramatically facilitated 
the data handling in Paper III and IV. Protein Center was further used to compare lists 
of phosphopeptides and phosphoproteins between replicates of the same sample as well 
as between different samples. Moreover, this tool also provided short information about 
functions for each protein and also presented known phosphorylation sites. Such 
information was convenient and very helpful to have while manually scrolling the lists 
to inspect the data. Also for visualization, Protein Center  played an important role, as it 
provided pictures covering the total sequences of a protein but highlighting the parts 
covered by our data as well as indicating the modifications regardless if they were 
previously known or not. 
 
 In genomics and proteomics experiments, what one usually has is an enormous list 
with genes/proteins regulated by abundance or as in phosphoproteomics, by 
phosphorylations. The big question at present in proteomics lab worldwide, as well as 
in our lab - is how we should find the biological relevance of our samples from this list. 
In Paper I, we claim that PSE could be such a novel tool and in Paper III and IV 
network analysis and data mapping on canonical pathways using IPA were used to 
visualize and to create hypotheses regarding the biological interpretation. What is 
delivered from such software tools for global analysis available today can of course not 
be considered as the truth but might still be helpful to get ideas of the type of molecules 
and their possible areas of function. However, specific manual interpretation and 
knowledge of the field in the research question was used to fine tune the hypotheses.  
Such hypotheses were then validated by orthogonal methods like western blot (Paper I, 
II, III), IF and pharmacological inhibitors in combination with ELISA (Paper I), 
siRNA (Paper II) and in cases where commercial antibodies were not available, like in 
Paper III, when there were no specific antibodies for certain phosphorylation sites, 
immunoprecipitation was used to “fish out” the total protein. Westernblot was then run 
on precipitates and the membrane was blotted with a pan phospho – antibody.  
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Importantly, after generation and validation of the hypothesis, the hypothesis which 
now can be termed as a strong, can be used in a feedback loop to drive and expand the 
project. While we now have a starting point, like for example an interesting protein 
regulated in apoptotic cells, we are able to perform targeted analysis of the same global 
data and search for known interacting partners or partners of the same signaling 
cascades as the candidate protein. In paper III, this feedback approach was used for 
upstream pathway walking by pinpointing the upstream kinases generating the specific 
phosphorylation on a regulated substrate, which in this case was the phosphorylation on 
Ser 897 on the EphA2 receptor and its upstream kinase Akt1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Workflow for signalomics experiments 
 
Aspects of phosphoproteomics 
Phosphoproteomics has already played and will most probably continue to play a 
significant role in our ability to understand molecular mechanisms that govern human 
cancers (287-290). Various technological platforms are now available for 
phosphoproteomic studies enabling us to address different aspects of tumor biology 
governed by phosphorylation-mediated signaling pathways (291). 
 
Cellular proteins in humans are predominantly phosphorylated on serine/threonine 
residues with a smaller extent of phosphorylation occurring on tyrosine residues. 
However, the overall low abundance of phosphoproteins complicates identification and 
characterization of this sub-proteome using standard mass spectrometry based methods. 
In addition to the problem of low abundance, phosphorylated peptides are, due to their 
phospho-groups in general more acidic than mainstream peptides, thereby complicating 
ioniziation in positive ion mode of mass spectrometry (292-293). Moreover, trypsin, 
which is the most commonly used enzyme for digestion of proteins to peptides prior to 
mass spectrometry, has difficulties to cleave next to a phosphorylation, resulting in 
large peptides which in general have poor fly ability in a mass spectrometer due to their 
size. However, digestion can be improved by using an additional enzyme 
complementary to Trypsin, like for example Lysozyme C.   
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  The challenges with global studies of phosphorylated peptides/proteins have spurred 
the development of molecular tools to preferentially enrich the phosphoproteome. 
Ferric ions was the first enrichment strategy and was exploited by biochemists to 
isolate phosphoproteins and phosphopeptides using immobilized metal affinity 
chromatography (IMAC)(249). Analogous to ferric ions, gallium (III) has also been 
shown to display affinity and selectivity to phosphopeptides (256). These enrichment 
strategies followed by mass spectrometry have convincingly proved to reveal the 
identity of the proteins and the sites of modification (260, 270, 294-303). One of the 
main aims of the current thesis was to set up a phopshoproteomic method; several 
experiments were performed using both IMAC-Fe and IMAC-Ga, off line coupled to 
MALDI-TOF/TOF. These experiments were somewhat successful for non-complex 
samples like α and β Casein, but always failed when applied to complex samples like 
total cell proteomes. In retrospect, we realized that the failure had little to do with 
choice of metal, but instead was an issue of extended pre-fractionation and qualities of 
the mass spectrometer.  One of the other advances that particularly enhanced the ability 
to enrich serine/threonine phosphopeptides is the technique based on titanium dioxide 
(TiO2) for selective enrichment of phosphorylated peptides (267, 285, 302, 304-306).  
 
While setting up a method for our phosphoproteomic studies, before choosing which 
strategy to use for enrichment of phosphorylated peptides from complex samples prior 
to mass spectrometry, we performed a comparative study between a kit using the 
IMAC-Fe-based method and a kit based on the TiO2 method. Their ability to enrich for 
phosphorylated peptides was analyzed by radiolabeling the phosphates with p32 and 
then measuring the p32-activity in the different phases. In our hands, as shown in figure 
8 the TiO2-method proved to give slightly better results by showing higher affinity for 
the phosphopeptides as well as giving higher yield during elutions and was thus our 
method of choice.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: TiO2 was the method we choose for enrichment of phosphorylated 
peptides. 
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As previously described in the section of Material and Methods, prefractionation using 
SCX and subsequent enrichment using TiO2 before analysis by LTQ – Oritrap Velos 
inspired by Villen et al (270) was set up for Paper III and was also further applied in 
Paper IV. By using SCX-based fractionation, peptides in the same fraction had a 
similar net charge; this is a great advantage when the next step is enrichment by TiO2. 
TiO2 has affinity for the phosphogroup but also for other highly electronegative 
structures and in a fraction were all peptides have similar net charge i.e. similar 
electronegativity, it will be more likely that phosphorylated peptides win the 
competition of binding TiO2 compared to those who are non phosphorylated (267-268). 
This phenomenon is believed to be due to that the electronegative oxygen of the 
phosphogroups has stronger affinity to parts of the structure of the TiO2 resin than the 
acidic residues and the C-terminals of the peptides. However, other structures of the 
TiO2 resin instead binds strongly to peptide C terminals which is why strong aromatic 
acids like 2.4-dihydroxybenzoic acid (DHB) or Glucolic acid, which have even 
stronger affinity for such structures, are used as blockers of such non phosphorylated 
acidic-peptide residues when equilibrating the resin as well in the buffer while binding 
the sample (267-268, 300, 305). 
 
 In general, studies using phosphoproteomics have clearly taken us beyond looking at 
mutations or other genetic variations commonly observed in cancers and are providing 
us insights into functional consequences of these changes in conferring survival 
advantages to cancer cells. Such studies are already being used as the basis for 
determining therapeutic options (290, 307-308). 
  
2.4.2 Biological perspectives  
One advantage of using the same model system in all four studies was that we now in 
the end can collect everything we have learned from each study to get a more holistic 
picture of signaling events regarding resistant mechanism against conventional 
radiotherapy in this model. Moreover, by observing signs that are pointing in the same 
direction in different studies, the different studies are somehow used as controls for 
each other. One example is up regulation of p38 which was found both in Paper I and 
Paper II in response to low LET IR. Interestingly, we have some indications of active 
p38 also in Paper IV since we found a phosphorylation on Ser 611 on TFIII in 
response to low LET IR. The predicted kinase of this site is p38 
(http://www.phosphosite.org), but further validation experiments need to be done to 
find out if this is true also in our system Moreover, the  activation of p38 has been 
reported downstream of IGF-1R in a previous study of U-1810 cells from our group 
(71). Together, these four studies strongly suggest that active p38 mediated signaling is 
a mechanisms used for protection against low LET IR in this model system. 
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Lessons about cellular signaling regarding the increased cell death observed in 
response to high LET IR in NSCLC cells resistant to low LET IR 
Beginning with Paper I and paper IV, high LET IR was proven to circumvent 
resistance mechanisms observed in response to low LET IR by forcing induction of 
apoptosis, which was evident as increased apoptotic morphology, increased caspase 3 
activation and activation of mitochondria through the pro-apoptotic BAK and BAX 
proteins. High LET IR has been proven beneficial for treatment of solid tumors and is 
today applied in the clinic to some extent (19, 309-315). However, at present high LET 
IR is not likely to become a clinical standard treatment in the same way as low LET IR 
because of the inconvenience of using the source as it requires a set up of large 
cyclotrons with limited beam times. Such sources are only present in a few places in the 
world, one being at the Svedberg laboratory in Uppsala. However, clinical benefits can 
also be achieved to a large extent by understanding the cellular signaling responsible 
for the improved tumor control in response to high LET compared to conventional 
radio therapy. Using such strategy may lead to identification of novel clinical targets 
which can be used to sensitize for conventional radiotherapy or possibly as markers to 
select patients particularly susceptible for high LET radiotherapy. The JNK-pathway 
was found to play a significant role upstream of the apoptotic signaling cascade in 
response to high LET IR, in particular involving MKK4, JNK and 14-3-3 σ. JNK 
signaling have been reported as a pro-apoptotic event in several studies (316) and as 
our data supported a pulsed early and late JNK response (fig 9) and we do see 
activation of MKK4 at 4h post high-LET IR this might indicate that MKK4 is involved 
in the late activation of JNK but cannot be responsible for the observed early JNK 
activation since it was already at 2h. When considering other signaling molecules 
involved, it is tempting to speculate that the non-receptor tyrosine kinase c-Abl is 
involved upstream of MKK4 as it has been shown to activate MKK4 and JNK via 
MEKK1-mediated signalling after conventional IR as well as other DNA damaging 
treatments (317-320). It was recently shown that an early initial JNK activation is 
required in order to trigger release of c-Abl from the adaptor protein 14-3-3, c-Abl is 
then directed into the cell nuclei which subsequently allow c-Abl and late JNK 
activation (321-323). This is in line with the observed reduction in 14-3-3σ in U-1810 
cells 4 hours after high-LET IR. Hence, the conditions fit to support that high-LET IR 
but not low-LET IR is capable of recycling c-Abl to the nucleus where c-Abl in turn 
activates JNK and initiate apoptosis in this system.  Further studies of c-Abl activation 
and localization in response to high-LET IR will clarify if this is the case. 
 
In addition to increased apoptotic signaling reported in Paper I, Paper IV is adding 
information about the perturbations in cellular signaling in response to high LET IR by 
suggesting that this quality of radiation interrupts protein synthesis. Hence, signaling 
pathways describing assembly of the RNA polymerase III complex responsible for 
expressing tRNA and eIF-signaling responsible for translation from mRNA to peptides 
sequences were found active in response to low LET IR, but suggested as deactivated 
in response to high LET IR. Interestingly, connections between JNK-signaling and 
eIF2-signaling have been previously reported, however it is not completely clarified  
 40 
 
how JNK1 and JNK2 are controlling the regulations. One suggestion is that JNK2 is up 
regulated while eIF2-signalig is deactivated (324). Importantly, the requirement of 
JNK-signaling for inducing apoptosis in response to high LET IR in our model system 
could be confirmed also on the functional level, as a specific pharmacological inhibitor 
of JNK, SP600125 efficiently also inhibited apoptosis induced by high LET IR. Hence, 
one may speculate that over expressing JNK is a potential strategy to sensitize NSCLC 
cells to conventional radiotherapy. 
 
Lessons about survival signaling controlled by members of the Eph/ephrin family in 
resistant prone NSCLC cells 
By the unsupervised screening of regulated genes in Paper II, it appeared that the 
developmental protein ephrin B3 was down regulated in NSCLC cells receiving 
combinational treatment by IR and the staurosporin analogue PKC 412. We found the 
regulation of ephrinB3 highly interesting since other members of the Eph/ephrin family 
have during the past few years emerged as important in oncogenic transformation in 
several cancer forms including lung cancer (325). However, the member, ephrin B3 
have not gained much attention in such matter before. Previous studies from the group 
of Boris Zhivotovsky had highlighted the radiosensitizing effects of PKC412 in U-1810 
cells and also observed an increased induction of mitotic catastrophe (77, 83). We also 
observed stress factors on the cells while using such treatment combination, as the cells 
decreased in number and changed their cellular morphology. In addition, these 
treatments also resulted in increased apoptotic signalling as cleavage of cytokeratin 18 
and PARP. Hence, our data from the gene array experiments generated the hypothesis 
that one mechanism which U-1810 cells use to protect themselves from the effects of 
conventional radiotherapy is to keep high levels of ephrin B3 in the system. To confirm 
our hypothesis and further elucidate the role of ephrin B3 in NSCLC cells, we silenced 
the expression of this gene. The effect of the silencing was unexpectedly striking, as we 
observed clear visible changes in the cellular morphology, very similar to those 
observed on the cells when they were treated with the combination of IR and PKC 412. 
We could also confirm increased PARP cleavage and increased apoptotic nuclear 
morphology and also some increase in nuclear morphology typical for cells going 
through mitotic catastrophe. When observing these effects, we become curious in if we 
could further boost the effects by irradiating the NSCLC cells after silencing ephrin B3. 
Doing so, it was evident that both nuclear morphologies typical for apoptosis and 
mitotic catastrophe increased significantly and cell growth was clearly interrupted. The 
cellular morphology which now was highly differentiated, with flattened, transparent 
and highly elongated cells that were at least 10-fold the size of normal NSCLC cells, is 
typical for cells which are going in to the state of senescence (326). Indeed, this 
appeared to be the case as cells with silenced ephrin B3 were staining blue in β-
galactosidase (β-gal) - assay. This effect was even clearer when cells with silenced 
ephrinB3 were further treated with IR and as much as 40% of the cells showed high β-
gal-staining. Knowing that senescent cells are arrested in G0/ G1(326) we performed 
studies of the cellular distribution of the cell cycle. As expected, cells with silenced 
ephrin B3 arrested in G1, but in contrast irradiated cells appeared to shortly get stacked 
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in G2/M having trouble to get through mitosis properly, however at least a part of the 
culture did not arrest for long but started to proliferate again. Interestingly, this was not 
the case when the irradiated cells also had lost expression of ephrin B3, thus only a 
small part of the cells were now left in G2/M while the majority of the cells  
accumulated in G1where they arrested and became senescent. Thus our data suggests a 
role of ephrin B3 as a driver, forcing the NSCLC cells to cycle also when they were 
having lesions in their DNA from irradiation that ideally would induce cell death. The 
results from Paper II encouraged us to continue to search for important players in 
signaling events controlled by ephrin B3. Consequently, we took on a 
phosphoproteomic approach in Paper III and searched unsupervised for differences in 
the overall profiles of phosphorylated proteins in cells with present or absent ephrin B3. 
More than 2000 phosphorylated protein were identified in this study and 150 of them 
were specifically phosphorylated only in presence of ephrin B3. One of the top 
regulated active networks mapped from these 150 proteins included another member 
from the Eph/ephrin family, the Eph A2 receptor. Only recently, during the past two 
years, the field of Eph A2 as a target for cancer therapy has exploded, since Eph A2 
have been discovered over expressed in several cancer forms, including lung cancer 
(127, 327-332). When ephrin B3 was present, we detected a phosphorylation on Ser 
897 on this receptor, a site reported as phosphorylated by Akt1 only when Eph A2 is 
bound by its ligand, ephrin A1(282). Total cellular levels of ephrin A1 was not changed 
by the presence or absence of the ephrin B3 ligand in our model. Nevertheless, our data 
suggested that ephrin B3 somehow inhibits the binding of ephrin A1 to the Eph A2 
receptor in the U-1810 cells. Interestingly, we also found Akt1 to be phosphorylated on 
Ser 129, only in presence of ephrin B3. As this site is known to be specifically 
phosphorylated by the serine/threonine kinase CK2 in Jurkat cells (283), it is interesting 
to speculate that this might be the case also in our model. CK2 is a kinase reported to 
have elevated levels in tumors and being high in signaling controlling hierarchy by 
having direct influence of perhaps as much as 20% of the so far identified 
phosphorylations sites (333), indeed it was found to be highly expressed also in our 
model system. HSP90 is another target of CK2(334) which in fact protects EphA2 from 
proteosomal degradation(284, 335). -  When realizing this, we went through our data 
again specifically searching for this chaperon protein. In accordance with this 
hypothesis, we did find a phosphorylated form of HSP90AA1 only in presence of 
ephrin B3. In addition more than 40% of the sequence was identified on HSP90AA1 in 
presence of ephrin B3 while no peptides from HSP90AA1 were detected when ephrin 
B3 was silenced. As the function of HSP90 is to protect proteins from degradation and 
EphA2 has been reported previously as a client of HSP90 (284, 335), our data strongly 
support such a mechanism also in our system, hence during validation experiments it 
appeared that silencing ephrin B3 did not only led to dephosphorylation of EphA2, it 
actually led to degradation of the total protein. In turn, the binding of ephrin A1 to 
EphA2 is known to cause tyronsine phosphorylation on the receptor and thereby 
mediate its down regulation(116). Thus one may speculate that - in absence of ephrin 
B3 this might also be the case in our system, as the phosphorylation on the Tyrosine is 
probably not detected with our method. Ephrin A1 is known as a tumor suppressor and   
has functions which involve repression of oncogenic signaling through receptor 
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Tyrosine phosphorylation further leading to attenuating growth factor induced 
activation of Ras. However, in the case of present ephrin B3 ligand, even though we 
still detected basal levels of ephrin A1 in our system, ephrin A1 is not properly binding 
the EphA2 receptor, thus EphA2 is losing its kinase capacity and instead act as a 
substrate to Akt1(282). A contradictive aspect of the non proliferative effects when 
ephrin A1 binds Eph A2 in tumor cells is that it appears to be the opposite in 
angiogenesis where ephrin A1 binding EphA2 instead stimulates migration (336-341). 
Yet, this phenomenon further states the importance to improve the knowledge of 
differential signaling via specific phosphorylation sites of signaling proteins rather than 
only focusing on protein identities as this might explain why interactions between the 
same proteins can mean different things in different situations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Potential mechanisms of radioresistance in NSCLC. Failure of 
proapoptotic activation of JNK, overactive protein synthesis as well as ephrin 
B3/EphA2 mediated activation of survival mechanisms which force cells to cycle 
instead of becoming senescent even though they are carrying damages in their DNA, 
are all mechanisms that may contribute to the radioresistant phenotype of NSCLC cells. 
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2.5 GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES  
 
The goals with this thesis were to use global methods for signaling studies in NSCLC 
cells. In particular, the main goal was to set up a platform for global assessment of 
phosphorylated proteins in complex samples. Such a platform was indeed established 
and was used in the two last papers of this thesis. From a biological and preclinical 
perspective, the aim was to gain novel insight of the cellular mechanisms that are 
responsible for the radioresistant phenotype expressed by NSCLC cells. Paper I and IV 
cover NSCLC cellular response to low and high LET IR while Paper II and III deal 
with the role of ephrin B3 – mediated signaling and how it affects radiosensitivity in 
NSCLC. The general conclusions are: 
 
 Experimental design: 
When performing global studies in cellular signaling, it is of high importance to 
plan the workflow as much as possible before starting. One way is to use the 
template workflow for signalomics, described in the section of Discussion 
Workflow for signalomics experiments. Hence, check that you have the 
prerequisite for each step. Note that the principle of “Garbage in gives garbage 
out” is valid for this workflow. Step 1 is crucial in this matter and one should be 
sure to define the control and comparative sample in a way that secure clear 
effects in the sample. For example, a certain treatment clearly induces 
measurable cell death in the sample. Thus, the last step, validation using 
orthogonal methods, can be tricky anyway but will be impossible if the input 
samples are not reflecting the signaling question. 
 
 Posphoproteomics 
Our platform for globally identifying phosphorylated proteins includes 
enriching for the phosphoproteome using SCX-fractionation and affinity based 
binding to magnetic TiO2 beads before nano-LC online to mass spectrometry 
based analysis. When analyzing complex samples like whole cellular 
proteomes, it requires a fast mass spectrometer with high sensitivity and proper 
fragmentation techniques e.g. HCD and ETD. Hence, Orbitrap Velos (Thermo 
Fisher Scientific) is a good choice. We could identify more than 2000 
phosphorylated proteins from NSCLC cells and the enriched fraction contained 
70-90% phosphorylated peptides compared to non phosphorylated ones. This 
numbers have similar quality as world leading laboratories for 
phosphoproteomics (265, 285) .  
 
 Radioresistance mechanisms of NSCLC cells 
Regarding our studies in response to low and high LET IR, we could conclude 
that one mechanisms hindering response to conventional low LET IR in 
NSCLC cells is failure of inducing apoptosis by pro-apoptotic JNK-signaling 
and subsequent activation of mitochondria by BAK and BAX. In addition, we  
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also report up regulation of pro-survival p38 MAPK signaling.  Furthermore, 
our data suggest that one way these cells use to resist low LET radiotherapy is 
to continually synthesize new proteins, illustrated in our studies by activation of 
the assembly of RNA-polymerase III complex and eIF2-signaling. 
 
In Paper II, we found that the developmental protein ephrin B3 was down 
regulated when combining PKC 412 and radiotherapy. A treatment which 
indeed increased cell death compared to single treatment of either PKC 412 or 
IR. NSCLC cells treated with the combination PKC 412 and IR showed 
pronounced changes in morphology and a similar morphology of enlarged, 
flattened and elongated cells was evident also when we silenced ephrin B3. We 
could conclude that NSCLC cells deficient of ephrin B3 either died (partly from 
mitotic catastrophe in G2/M) or actually went in to a senescent state, arrested in 
G1. In addition, as a follow up from Paper II, in Paper III - we purpose a 
survival pathway, where ephrin B3 regulates P- Ser 129 on Akt1 and P- Ser 897 
on Eph A2 in a signaling circuit that most probably contributes to the 
radioresistant phenotype of U-1810 cells. The mechanisms described in this 
section may all be clinically relevant for treatment of NSCLC and deserves to 
be further investigated.  
 
2.5.1 Future perspectives 
All studies in this thesis are preclinical and each of them has generated candidates 
which may be used for future targeted therapy in NSCLC either alone or as sensitizer 
for conventional radiotherapy. However, the way is still long before any of these targets 
can actually reach the clinic. 
 
 Perhaps the most interesting part of this thesis is the novel finding of ephrin B3 as a 
regulator NSCLC radiotherapy resistance and as a regulator of the phosphorylation on 
Ser 897 on EphA2. Ephrin B3 has not been connected to radiosensitivity before and is 
not reported as one of the ligands of EphA2. Yet we have not revealed if ephrin B3 is 
binding the EphA2 receptor directly or if the regulation is indirect. We only know that 
the original ligand ephrin A1, most probably does not bind if ephrin B3 is present in the 
cells. The details about the molecular interplay in the relationship between ephrin B3, 
ephrin A1 and EphA2 probably play important roles for the grade of radiosensitivity of 
these cells and would be interesting as follow up study. Inhibitors of EphA2 are already 
under investigation and the field of this receptor as a target for cancer therapy is a 
highly vibrating and its regulation in NSCLC is of highest interest. Validation of the 
regulation of phosphoylation on Ser 897 in a larger cohort of clinical material would be 
highly interesting. A problem when it comes to validation of many novel 
phosphorylation sites is the lack of specific antibodies; this is the case also for 
phosphorylation of Ser 897 on EphA2. Under such circumstances, the use of selected 
reaction monitoring (SRM)-mass spectrometry (342) for validation would be ideal and 
definitely an interesting future experiment to run.  
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 The protocol used to analyze phosphorylated proteins have been set up for cell lines, 
however when creating this protocol, in the back of our mind, the plan was to use the 
protocol also for clinical material in the future. Hence, the basic of the protocol is 
already compatible for clinical material, but further optimization is required to inhibit 
dephosphorylation of the sample during collection from the clinic. Moreover, 
optimization is needed also in the matter of down scaling volumes needed in the step of 
SCX-fractionation to reduce starting amount of material but still keep high levels of 
identified phosphorylated proteins. Such protocol is also dependent on the development 
in the field of mass spectrometers, this field have developed extremely fast during the 
past 5 years and it is not impossible that we soon can measure even very low amounts 
of phosphorylated peptides which will reduce the amount of start material needed and 
ultimately benefit a translation of our pre-clinical protocol to a clinical protocol for 
phosphoproteomics. 
 
Surgery, chemo – and radiotherapy have been the major treatment strategy for lung 
cancer ever since the 70’s. However, targeted therapies mainly in the form of kinase 
inhibitors are now in clinical use and directing the way towards more personalized 
treatment forms ultimately giving improved efficacy and fewer side effects. Kinases are 
important for cellular signaling in caner which is the reason why they are targeted in 
cancer therapy today, but one should not forget that they are important also for cellular 
signaling in healthy cells. A kinase may generate phosphorylation of hundreds of sites 
on different substrates which explains the high impact on major functions also in 
healthy cells. In addition, it is difficult to design specific kinase inhibitors, as many 
kinases are similar in their active site, which even further reduces selectivity and 
specificity, meaning that we still have very little control of which signaling pathways 
that we are manipulating with these drugs. Indeed, severe side effects are reported also 
for several of the kinase inhibitors (343-346). However, some results of such drugs are 
promising and this development of cancer treatment is definitely a step in the right 
direction. Nevertheless, an alternative way to gain even higher control of which 
signaling pathways that are affected in the cell would be to target the actual site of 
phosphorylation on the substrate instead of the active site on the kinase. This is even 
more beneficial if the site of phosphorylation on the substrate is generated specifically 
from one kinase, which is the case in most situations. However, even in cases when a 
phosphorylation site has several upstream kinases, the site will still, most likely be 
more specific than a pleiotropic kinase. A model for potential target points on 
phosphorylated substrates identified in paper III is presented in figure 10. 
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Figure 10: Model of potential target sites in NSCLC. Most targeted therapies today 
inhibit the active site on a kinase (yellow dots). Thus, hundreds of substrates (small 
black dots) will be affected. If we instead target specific phosphorylation sites (a part of 
a small black dot) in the future, we may have improved control on which specific 
signaling path that is manipulated (here illustrated by the straight line reaching from 
CK2 via Akt to EphA2). 
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